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Summary 
Covering over 70% of the Earth's surface, marine ecosystem is the home for a wide 
variety of animal and plant species whose number greatly exceeds that of terrestrial ones. 
Amongst those biodiversity, microbial world represents a potential research object to be 
explored as the recent investigations on marine bacteria have given the impact to the entire 
world as a source of bioactive metabolites producers. The area of application of biologically 
active compounds from bacterial origin is wide, involving agricultural, industrial, and 
pharmaceutical sectors. 
Japan is surrounded by sea and, consequently rich in marine resources. Joining to the 
world research arena, our research group is engaged with the investigations related to the 
marine environment. In this regard, marine microorganisms and their respective metabolites 
have drawn our special attention due to their strong bioactive properties, featuring them to be 
excellent pharmaceutical agents. More specifically, different kinds of pigmented compounds 
isolated from marine bacteria, along with their biological properties are one of the currently 
ongoing research projects of our laboratory. 
As a result of this research, two kinds of pigments, i.e. red and purple colored 
compounds were isolated from marine Pseudoalteromonas strains 1020R and 520P1. The two 
strains along with other 83 bacterial strains were previously found in the Pacific Ocean at a 
depth of 320 m, near to Cape Muroto, Kochi Prefecture. Structural and biological properties 
of the two pigmented compounds are currently under intensive investigations. 
Structural investigations revealed that the red pigment represents so-called prodigiosin 
and its close related analogs, which have a common pyrrolyldipyrromethene core structure. 
These compounds are famously known for their broad range of biological properties, 
including antibiotic, immunosuppressive, and above all anticancer activities against nearly 60 
cancer cell lines, with no or very little effect on normal functioning cells. The purple pigment 
was found to consist of violacein and a little amount of deoxyviolacein, which have the 
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similar biological activities as prodigiosins, except immunomodulatory effect. 
Current research is a continuation of previous investigations and outlines the findings 
recently obtained from the study of these pigments, and deals with the following tasks: 
1. Structural analysis of an unknown compound of the red pigment, including the 
stability investigations of the individual compounds of the red pigment.  
2. Investigations on the mechanisms of action involved in cytotoxicity of the red- 
pigmented prodigiosin and purple-pigmented violacein compounds on the molecular level. 
Previous studies showed that the red pigment contains four individual pigments, all of 
which belong to the prodigiosin family compounds. Chemical structures of three out of four 
were successfully determined on the basis of mass- and NMR spectroscopy methods, and only 
the structure of the pigment 1 was not determined and remained in doubt. However, recent 
investigations have revealed that the red pigment may actually contain seven individual 
compounds. These compounds are named as P-1, P-2 (previously described as pigment 1), 
P-3, P-4, P-5, P-6 and P-7. Pigments whose chemical structures were previously determined 
were P-4 as 2-methyl-3-pentylprodiginine or prodigiosin, P-5 as 2-methyl-3-hexylprodiginine 
and P-6 as 2-methyl-3-heptylprodiginine. These were typical red colored compounds differing 
from each other only by the length of side alkyl chain. Thus, the chemical structures of P-1, 
P-2, P-3 and P-7 have become unknown. 
In this study, separation and structure elucidation analyses of P-2 of the red pigment are 
described. Structural analyses of P-1 were not carried out due to its instability, which 
decomposed into other unknown compounds, thus making our task impossible to bring into 
effect. Biological properties of the individual compounds of the red pigment were 
investigated by the cell cytotoxicity assays on U937, HL60 and K562 leukemia cell lines. An 
attempt was also made to investigate the molecular mechanisms of cytotoxicity action of the 
individual compounds of the red pigment, including violacein from 520P1 bacterial strain. An 
impact of the environmental conditions, i.e. temperature and solvents were studied to find the 
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logical reasons of the instability of the individual compounds of the red pigment during their 
preservation period. 
As a result of this research, the chemical structure of P-2 in the red pigment, which 
remained unknown in the previous study, was determined to be 2-methyl-3-butylprodiginine 
according to mass- and NMR spectroscopy methods. The determined structure revealed that it 
is another close related analog of 2-methyl-3-pentylprodiginine or prodigiosin, differing from 
it only by lacking one –CH2 group in side alkyl chain. Although, this chemical structure was 
previously predicted to be existed in literature and by our research group too, according to its 
MS data, it was not investigated by NMR methods, and thus, making those conclusions 
widely not confirmed. The chemical structure of P-1 copurified together with P-2 was not 
determined due to its extreme instability, which decomposed during accumulation and 
preservation. This instability led to the investigation on the impact of environmental 
conditions to the individual compounds of the red pigment, and the following study revealed 
that there are many factors that may affect on the stability of the pigments. Particularly, the 
nature of solvents and temperature were found to have the most profound effects on the 
stability of the pigmented compounds, along with a previously reported light effect. 
Cell cytotoxicity assays of the red pigment and its individual compounds were performed 
on U937, HL60 and also K562 leukemia cancer cells using the MTS assay. The compounds 
tested showed cytotoxic effect, with slightly different IC50 values. Among the pigments, P-4, 
i.e. 2-methyl-3-pentylprodiginine or prodigiosin showed the highest apoptotic effect, followed 
by P-5 or 2-methyl-3-hexylprodiginine and P-6 or 2-methyl-3-heptylprodiginine. 
The molecular mechanism of the cytotoxicity of the red pigment compounds was 
investigated by evaluating the effect of the pigments on enzymes involved in the intracellular 
signal transduction. The red pigment compounds had strong inhibitory effect against the 
activities of protein tyrosine phosphatase 1B (PTP1B) and protein phosphatase 2A (PP2A) 
tested in this study. However, the red pigment showed no effect on protein kinases, namely 
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the catalytic subunits of protein kinase C (PKC) and protein kinase A (PKA), along with PKC 
subfamily isozymes as well as Src-protein tyrosine kinase (Src-PTK) and 
calmodulin-dependent protein kinase (CaM kinase). On the other hand, violacein from 520P1 
strain showed strong inhibitory effect against the catalytic subunits of PKA and PKC and 
some of PKC family isozymes, but having relatively low effect on protein phosphatases. 
 
The aim 
The aim of this investigation was to perform structural analyses of unknown compounds 
present in the red pigment produced by a marine bacterial strain 1020R belong to 
Pseudoalteromonas species of bacteria and to investigate molecular mechanisms of 
cytotoxicity actions of the red pigment and its individual compounds as well as violacein 
against cancer cells. Stability of the red pigment compounds was also aimed to investigate as 
they showed a tendency to decompose into other compounds when the samples were kept 
even in a dark place to avoid a light which is believed to be an initiator stimulus for their 
decomposition. 
 
The novelty of the work 
For the first time in this research, the chemical structure of P-2 of the red pigment was 
determined to be 2-methyl-3-butylprodiginine by high-resolution mass-spectroscopical 
(HR-MS) and NMR spectroscopy methods. 
Prodigiosins and violacein effects on protein kinases, including protein kinase A (PKA), 
protein kinase C (PKC) and PKC family isozymes as well as protein phosphatases, such as 
protein phosphatase 2A (PP2A) and protein tyrosine phosphatase 1B (PTP1B) was studied. 
Structure activity relationship studies of the individual compounds of the red pigment 
were carried out to investigate the biological properties of prodigiosin compounds which 
differ from each other only by the side alkyl chain length. 
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Chapter I 
Introduction 
Marine pigmented bacteria and their bioactive metabolites* 
 
Abstract 
Over the last 50 years, the search for bioactive compounds from marine natural resources, 
including microorganisms has rapidly increased, as the development of modern technologies 
has allowed access to this diverse ecosystem. This scientific enterprise has already started 
giving fruits as the aquatic world has proved to produce not only compounds that are common 
to terrestrial sources, but also unique molecules that are only found in marine organisms. 
Considering that the oceans cover a vast area of our planet, finding bioactive compounds with 
excellent pharmaceutical properties is promising. In this regard, marine bacteria are of special 
interest as they are extremely numerous and biotechnologically favorable for cultivation. 
Despite the enormous difficulty in isolating and harvesting marine bacteria, microbial 
metabolites are increasingly attractive to science because of their broad-ranging 
pharmacological activities. The secondary metabolites from marine bacteria, especially those 
with unique color pigments, not only play an important role in bacterial life, but also have 
diverse biological properties such as antibiotic and anticancer activities. The latter is of 
special interest due to the consistent requirement for chemotherapeutic drugs with high 
selectivity towards malignant cells. As the number of such bioactive compounds is 
continuously increasing, investigations on their molecular mechanisms of action are now 
required to be able to select and develop drugs. This current review, based on accumulated 
data in the literature, gives an overview of the pigmented natural compounds isolated from 
bacteria of marine origin. It comprises the biological activities of marine compounds, 
including recent advances in the study of pharmacological effects and other commercial 
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applications, in addition to the biosynthesis and physiological roles of associated pigments. 
Special chapter was also composed to describe the pigmented cytotoxic compounds isolated 
from marine bacteria, and discuss their molecular mechanisms of action in preventing tumor 
growth. Chemical structures of the bioactive compounds discussed in this review are also 
presented. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*This review combines the contents of the two review papers submitted for the publication in 
Evidence-Based Complementary and Alternative Medicine, vol. 2011, Article ID 670349, 2011. 
doi:10.1155/2011/670349 and the forthcoming book “Marine Biomaterials: Isolation, Characterization and 
Applications,” (Taylor & Francis Group).
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1.1. Marine bacteria and its role in life sciences 
A wide variety of diseases and medical problems represent a challenging threat to humans, 
who since ancient times have searched for natural compounds from plants, animals, and other 
sources to treat them. Although the process of finding effective treatments against fatal 
diseases is difficult, extensive searches for natural bioactive compounds have previously 
yielded some successful results. The isolation and identification of specific natural 
compounds led to the development of folk medicine, and humans learned to separate the 
isolates into medicinal drugs, which could be used to treat different diseases, and poisonous 
substances, which could be used for non-medicinal purposes (i.e., during tribal wars, hunting, 
etc.). Statistically, at least 50% of the existing drugs that are used to treat human illnesses are 
derived from natural products, most of which are obtained from terrestrial organisms [1]. 
However, due to continuous and exhaustive research, land-based natural bioactive compounds 
have become increasingly difficult to find. Instead, water-based natural compounds have 
become a more promising source, not only from a pharmacological view, but also for 
industrial and commercial applications. 
Theoretically, life is considered to have originated in the sea and, as a result of 
evolutionary changes, developed into a wide variety of diverse biological systems. The 
Earth’s surface consists of 70% water, which is inhabited by 80% of all life forms [1], and 
consequently aquatic organisms have a greater diversity than their terrestrial counterparts. As 
research into the marine environment is still in its early phases, many mysteries associated 
with aquatic fauna and flora have yet to be discovered. Therefore, the marine environment has 
recently become an attractive research subject for many investigations, because of its rich 
biodiversity. Despite being comprised of a diverse ecosystem, the search for marine 
metabolites is difficult because of the inaccessibility and non-culturability of the majority of 
organisms [2]. Nevertheless, the existing technologies like deep seawater pumping facilities, 
scuba diving, and other available equipments, have facilitated investigation of the sea 
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environment. As a result, scientific research has increasingly focused on marine biochemistry, 
microbiology, and biotechnology. 
Microorganisms and their isolates represent a major source of undiscovered scientific 
potential. It should be noted that the number of microbial organisms isolated from the vast 
ocean territories continues to increase each year. Consequently, natural products isolated from 
microorganisms inhabiting environments other than soil are an attractive research tool, not 
only for biochemists and microbiologists, but also for pharmacologists and clinicians. Laatsch 
[3] described the isolation and description of nearly 250 marine bacterial metabolites versus 
150 isolated from terrestrial bacteria between 2000 and 2005. Research into marine 
microorganisms and their metabolites has therefore become a major task in the search for 
novel pharmaceuticals. 
Although many compounds show promising biological activities, it is difficult to point 
out any particular bioactive agent that has readily been commercialized as a medicine. 
Currently, 13 natural products isolated from marine microorganisms are being tested in 
different phases of clinical trials, and a large number of others are in preclinical investigations 
[4], thus highlighting the potential of marine natural compounds. 
Despite thousands of marine bioactive compounds having been isolated and identified, in 
this paper, we will focus on the pharmacologically active pigmented compounds produced by 
marine microorganisms exhibiting in vitro or in vivo biological activities. Although 
pigmented compounds produced by terrestrial bacteria are beyond the scope of this review, 
specific examples will still be mentioned for comparative purposes, to outline common 
biological activities or because identical pigments were isolated from both types of 
microorganisms. 
 
1.2. Marine microorganisms and their bioactive isolates 
Marine and terrestrial microfloras differ from each other due to the influence of their 
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respective environmental conditions. Microorganisms living in the sea must be able to survive 
and grow in the water environment with low nutrition, high salinity, and high pressure. That is 
why most bacteria isolated from seawater are Gram-negative rods, as it is postulated that their 
outer membrane structure is evolutionarily adapted to aquatic environmental factors. Marine 
microorganisms can be divided on the basis of habitat into psychrophiles (living at low 
temperatures), halophiles (living at high salinity), and barophiles (living under high pressure). 
Although these characteristics highlight the differences between marine and terrestrial 
microorganisms, it remains difficult to separate bacterial genera on the basis of habitat due to 
the ubiquitous presence of similar species in both environments. As such, most bioactive 
compounds have been isolated from bacteria in both environments. 
Marine bacteria, however, are attractive to researchers because they can potentially 
produce compounds with unique biological properties [5]. Until now, marine Streptomyces, 
Pseudomonas, Pseudoalteromonas, Bacillus, Vibrio, and Cytophaga isolated from seawater, 
sediments, algae, and marine invertebrates are known to produce bioactive agents. They are 
able to produce indole derivatives (quinines and violacein), alkaloids (prodiginines and 
tambjamines), polyenes, macrolides, peptides, and terpenoids. Examples of 
bioactive-pigmented compounds isolated from marine (and some terrestrial) bacteria are 
discussed below. 
 
1.3. Pigments from marine bacteria 
1.3.1. Carotenes  
Carotenes are polyunsaturated hydrocarbons that contain 40 carbon atoms per molecule and 
are exclusively synthesized by plants. They are orange photosynthetic pigments important for 
plant photosynthesis. Recently, an unusual halophilic bacterium, which requires 15–25% salt 
for its normal growth, was found in Santa Pola near Alicante and on the Balearic island of 
Mallorca, Spain. It appeared to be red or pink due to a wide variety of isoprenoid compounds 
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(phytoene, phytofluene, lycopene, and β-carotene) produced by this prokaryote. Oren and 
Rodríguez-Valera [6] investigated red-pigmented saltern crystallizer ponds in these areas of 
Spain and demonstrated that the pigments were carotenoid or carotenoid-like compounds 
produced by halophilic bacteria related to the Cytophaga-Flavobacterium-Bacteroides group. 
Thus, it has been shown that Salinibacter is an important component of the microbial 
community that contributes to the red coloration of Spanish saltern ponds. 
Astaxanthin is one of the carotenoids that have commercial value as a food supplement 
for humans and as food additives for animals and fish (Fig.1.1). A carotenoid biosynthesis 
gene cluster for the production of astaxanthin has been isolated from the marine bacterium 
Agrobacterium aurantiacum [7]. Recently, another astaxanthin-producing marine bacterium 
was isolated and identified as Paracoccus haeundaensis [8]. 
 
Fig.1.1. Astaxanthin 
 
1.3.2. Phenazine compounds 
Phenazines are redox-active, small nitrogen-containing aromatic compounds produced by a 
diverse range of bacterial genera, including Streptomyces (terrestrial), Pseudomonas 
(ubiquitous), actinomycetes (terrestrial and aquatic), Pelagibacter (aquatic), and Vibrio 
(aquatic), under the control of quorum sensing [9,10] (Fig.1.2). These compounds were 
subjected to extensive studies due to their broad spectrum of antibiotic activities against other 
bacteria, fungi, or plant/animal tissues [11-17]. Phenazine color intensity may vary among the 
derivatives and range from blue, green, purple, yellow, red to even brown [13,18]. More than 
6,000 phenazine derivatives have been identified and described during the last two centuries 
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[14]. 
Maskey et al. [18] reported the isolation of two yellow pigments from the marine 
Pseudonocardia sp. B6273, a member of the actinomycetes. Structural investigations 
identified the two pigments as novel phenazostatin D, inactive against the tested 
microorganisms, and methyl saphenate, a known phenazine antibiotic. Li et al. [19] also 
reported the isolation of a novel phenazine derivative with cytotoxic effects against P388 cells, 
together with six previously identified compounds from the marine Bacillus sp., collected 
from a Pacific deep-sea sediment sample at a depth of 5059 m. A novel phenazine derivative 
with antibiotic activity, identified as 5,10-dihydrophencomycin methyl ester, along with 
(2-hydroxyphenyl)-acetamide, menaquinone MK9 (II, III, VIII, IX-H8), and phencomycin, 
was isolated from an unidentified marine Streptomyces sp. by Pusecker et al [20]. 
Pyocyanin and 1-hydroxyphenazine also down-regulate the ciliary beat frequency of 
respiratory epithelial cells by reducing cAMP and ATP, alter the calcium concentration by 
inhibition of plasma membrane Ca2+-ATPase, and induce death in human neutrophils [15, 16, 
21]. Due to the abundance and biotechnological application of Pseudomonas aeruginosa 
phenazines, pyocyanin and pyorubrin have also been suggested as food colorant pigments 
[13]. 
        
Methyl saphenate     Phencomycin 
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Phycocyanin    1-hydroxyphenazine 
 
 
5,10-dihydrophenazine-1,6-dicarboxylate (5,10-dihydrophencomycin methyl ester) 
Fig.1.2. Phenazine derivatives. 
 
1.3.3. Quinones 
Quinones are additional colored compounds with an aromatic ring structure that have been 
isolated from marine environment [22,23] (Fig.1.3). Quinone derivatives range in color from 
yellow to red, exhibit antiviral, antiinfective, antimicrobial, insecticidal, and anticancer 
activities, and have many commercial applications as natural and artificial dyes and pigments 
[24,25]. 
Streptomyces sp. B6921 strain produced glycosylated pigmented anthracycline 
antibiotics, including fridamycin D and two new compounds, named himalomycin A and B, 
each of which displayed similar levels of strong antibacterial activity against Bacillus subtilis, 
Streptomyces viridochromogenes (Tü 57), S. aureus, and Escherichia coli. This strain also 
produced rabelomycin, N-benzylacetamide, and N-(2'-phenylethyl) acetamide [23]. Two 
novel pigmented antitumor antibiotics, chinikomycin A and B, together with manumycin A, 
were isolated from a marine Streptomyces sp. strain M045 [26]. The two chlorine containing 
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quinone derivatives were shown not to have antiviral, antimicrobial, and phytotoxic activities; 
however, they exhibited antitumor activity against different human cancer cell lines. 
Chinikomycin A selectively inhibited the proliferation of mammary cancer, melanoma, and 
renal cancer cell lines, while chinikomycin B showed selective antitumor activity against a 
mammary cancer cell line [26]. 
Other bacteria, including a marine isolate Pseudomonas nigrifaciens (later reclassified as 
Alteromonas nigrifaciens), produce the blue pigment indigoidine [27]. Kobayashi et al. [28] 
isolated a new violet pigment with an alkylated indigoidine structure from Shewanella 
violacea, a deep-sea bacterium from sediments of Ryukyu Trench at a depth of 5110 m. This 
pigment was established as 5,5'-didodecylamino-4,4'-dihydroxy-3,3'-diazodiphenoquinone- 
(2,2') based on X-ray diffraction analysis of single crystals. It does not have antibiotic 
activity against E. coli; however, it could potentially be used as a dye because of its high 
stability and low solubility. Thus, it could be suitable for industrial applications. 
 
5,5'-didodecylamino-4,4'-dihydroxy-3,3'-diazodiphenoquinone-(2,2') 
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Fridamycin D: R1=H, R2=a, R3=b; 
Hymalomycin A: R1=d, R2=a, R3=b; 
Hymalomycin B: R1=d, R2=c, R3=H 
 
 
Chinikomycin A 
Fig.1.3. Quinones. 
 
1.3.4. Melanins 
Vibrio cholerae, Shewanella colwelliana, and Alteromonas nigrifaciens were some of the first 
marine bacterial strains described to produce melanin or melanin-like pigments [29-32]. The 
pigment synthesized by Vibrio cholerae was reported to be a type of allomelanin derived from 
homogentisic acid [33]. Melanin formation in V. cholerae is a consequence of alterations in 
tyrosine catabolism and not from the tyrosinase-catalyzed melanin synthetic pathway. 
Cellulophaga tyrosinoxydans was reported to have tyrosinase activity and produce a yellow 
pigment suggested to be a pheomelanin [34]. 
The most illustrative example of melanin-producing marine bacteria is the actinomycetes. 
This is particularly the case for the genus Streptomyces, from which most compounds with 
known biological activity have been isolated [35]. All Streptomyces strains are reported to use 
tyrosinases in the synthesis of melanin pigments [36]. Another important 
melanin-synthesizing bacterium is Marinomonas mediterranea, which produces black 
eumelanin from L-tyrosine [37]. 
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1.3.5. Other pigmented compounds 
Scytonemin, a yellow green pigment isolated from aquatic cyanobacteria, forms when the 
bacteria are exposed to sunlight (Fig1.4). It protects bacteria by preventing about 85–90% of 
all UV-light from entering through the cell membrane [38]. High UV-A irradiation inhibited 
photosynthesis and delayed cellular growth until sufficient amounts of scytonemin had been 
produced by the cyanobacteria. Scytonemin may also have anti-inflammatory and 
antiproliferative activities by inhibiting protein kinase Cβ (PKCβ), a well-known mediator of 
the inflammatory process, and polo-like protein kinase 1 (PLK1), a regulator of cell cycle 
progression [39]. In addition, scytonemin inhibited phorbol-induced mouse ear edema and the 
proliferation of human umbilical vein endothelial cells. 
Recently, two γ-Proteobacteria strains of the genus Rheinheimera were isolated from the 
German Wadden Sea and from Øresund, Denmark that produced a deep blue pigment [40]. 
Structural analysis of the pigment revealed that this new compound has no similarity with any 
known blue pigments, like violacein and its derivatives. Due to its blue color and marine 
origin, the new pigment was named glaukothalin (from Greek glaukos “blue” and thalatta 
“sea”). The ecological role and biological activities of glaukothalin are currently under 
investigation. 
AM13,1 strain, which was identified to belong to the Cytophaga/Flexibacteria cluster of 
North Sea bacteria, was found to produce yellow tryptanthrin, a rare compound that had never 
before been found in bacteria [41]. This compound was suggested to be a biocondensation 
product of anthranilic acid and isatin and exhibited a broad yet moderate antibiotic activity. 
Thus, the yellow color of the AM13,1 colonies was potentially due to their tryptanthrin 
content. In another yellow cultured Hel21 strain, pigment color may be a consequence of 
carotenoid zeaxanthin or one of the many vitamin K derivatives (e.g., menaquinone MK6) 
[41]. 
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Scytonemin     Tryptanthrin 
Fig.1.4. Other pigmented compounds. 
 
Bioactive pigments from marine bacteria are summarized in Table 1.1. 
Table 1.1. Biologically active pigmented compounds isolated from marine bacteria 
Pigment Activity Bacterial strains References 
1. Astaxanthin (carotene) 
2. Cycloprodigiosin 
 
 
3. 5,10-dihydrophencomy 
  cin methyl ester 
4. Fridamycin D, 
Himalomycin A, 
Himalomycin B 
5. Heptyl prodigiosin 
6. Melanins 
 
7. Methyl saphenate 
 (phenazine derivative) 
Anti-oxidation 
Immunosuppressant; 
Anticancer; 
Antimalarial 
Antibiotic 
 
Antibacterial 
 
 
Antiplasmodial 
Protection from UV 
irradiation 
Antibiotic 
 
Agrobacterium urantiacum 
Pseudoalteromonas 
denitrificans 
Streptomycete sp. 
Streptomycete sp. B6921 
 
α-Proteobacteria 
Vibrio cholerae 
Shewanella colwelliana 
Alteromonas nigrifaciens 
Cellulophaga 
tyrosinoxydans 
Pseudonocardia sp. B6273 
 
[7] 
[42], [43],  
[44] 
 
[20] 
 
[23] 
 
 
 
[45] 
[29], [30] 
[29], [32] 
[31] 
[34] 
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8. Phenazine-1-carboxylic 
 acid 
9. Prodigiosin 
 
 
10. Pyocyanin and 
pyorubrin 
11. Scytonemin 
 
 
 
12. Tambjamines 
 (BE-18591, pyrrole and 
 their synthetic analogs) 
13. Tryptanthrin 
 
15. Violacein 
Antibiotic 
 
Antibacterial; 
Anticancer;  
Algicidal 
Antibacterial 
 
Protection from UV 
irradiation 
Anti-inflammatory, 
anti-proliferative 
Antibiotic, anticancer
 
 
Antibiotic 
 
Antibiotic; 
Antiprotozoan; 
Anticancer 
Pseudomonas aeruginosa 
 
Pseudoalteromonas rubra 
Hahella chejuensis 
 
Pseudomonas aeruginosa 
 
Cyanobacteria 
 
 
 
Pseudoalteromonas 
tunicate 
 
Cytophaga/Flexibacteria 
AM13,1 strain 
Pseudoalteromonas 
luteoviolacea 
Pseudoalteromonas 
tunicata 
Pseudoalteromonas  sp. 
520P1 
Collimonas CT 
[18] 
 
[14] 
 
[46]  
[47] 
 
[13] 
 
[39] 
 
[48], [49] 
 
 
[41] 
 
[50], [51] 
[52] 
[53]  
 
[54] 
 
[55] 
 
1.4. Antitumor pigments from marine bacteria 
Transformation of normal cells to malignant cells is known to occur as a result of mutagenesis, 
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which has as a consequence the uncontrollable and abnormal multiplication of these cells 
within the body. Chemotherapy, the use of biologically active chemical compounds to 
interrupt and stop the growth of cancer cells, remains one of the most effective ways to cure 
cancer. However, the lack of effective chemotherapeutic drugs that can completely annihilate 
cancer cells remains an unsolved problem for modern science. Finding those desirable 
bioactive compounds has become a challenging task for researchers facing the limited 
efficacy of drugs used in clinical practice. Another challenge for the treatment of cancer is the 
ability of cancer cells to develop chemoresistance against drugs. Therefore, highly effective 
chemical compounds that can selectively eliminate tumor cells while not affecting normal 
cells are still in urgent demand. The newly designed drugs should preferably have selective 
inhibitory effects towards molecules that initiate anti-apoptotic mechanisms, while inducing 
pro-apoptotic proteins [56]. 
It is estimated that more than 50% of the 100 isolates obtained from marine sources are 
potentially useful bioactive substances [57]. Most of these compounds have either antibiotic 
or cytotoxic activities. Thus, in the period between 1998 and 2008, 592 marine compounds 
with cytotoxic activity were reported to have entered the stage of preclinical investigation. 
During this period, other 666 chemicals demonstrated antibiotic activities including 
antibacterial, antifungal, antihelmintic, antiprotozoal and antiviral activities, as well as 
anticoagulant, anti-inflammatory and antiplatelet effects, which have impact on the 
cardiovascular, endocrine, immune, and nervous systems [58]. Among these active 
metabolites, the compounds from marine bacteria are of special interest. 
While most of these compounds are reported to have potential antibiotic activities, a 
number of them also show cytotoxic effects [59]. The chemical spectrum of antitumor 
compounds derived from marine bacteria is wide, including indolocarbazoles, polyketides, 
alkaloids, isoprenoids (terpenoids) and even peptides (Table 1.2). 
Despite thousands of bioactive metabolites having been isolated from marine bacteria, 
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this chapter focuses only on colored compounds which have demonstrated either in vitro or in 
vivo apoptotic effects against cancer cells. Table 1.2 summarizes some of the bioactive 
antitumor pigments isolated from marine bacteria. The listed compounds do not show equal 
effects to all kinds of tumor cells, but they are rather selective to particular types of cells, 
showing cell type-specific action. This may be the reason why the bioactivity of the 
compounds is expressed in different half effective concentrations such as IC50 (IC70), GI50, 
TGI50, LC50, LD50, EC50, ED, GIC, and MIC (Table 1.2). At present, the true bioactivity of 
some compounds regarding selectivity and sensitivity towards cancer cells is unknown. For 
this reason, finding these values through further research will be necessary to be able to select 
suitable tumor cell lines that are more sensitive to the compounds of interest, as a 
pre-requisite for drug development. Although the cytotoxic compounds discussed below 
belong to a specific bacterial family, it is well known that one specific compound can be 
produced by many different species of bacteria, regardless if they are from terrestrial or 
marine origin. This indicates that the same or similar gene clusters responsible for the 
production of specific biomolecules may exist in many different species of bacteria, probably 
as product of the horizontal transfer of gene clusters among them. 
 
1.4.1. Cytotoxic pigments from marine actinomycetes 
When referring to pigmented cytotoxic compounds isolated from aquatic flora, marine 
Pseudoalteromonas, cyanobacteria, and especially Streptomyces stand out as they are the most 
important sources of these active metabolites. Terrestrial Streptomyces sp., first described by 
Waksman and Henrici [60], has proved to be the richest source of compounds with biological 
activities among bacterial species. Nearly 75% of the active metabolites isolated from 
Streptomyces have antibiotic and antitumor activities [61]. In a survey of active metabolites 
isolated from microorganisms, published in The Journal of Antibiotics between 1984 and 
1993, Miyadoh [61] reported that actinomycetes are the most important sources of bioactive 
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compounds, with a total of 93% of all antitumor antibiotics having been isolated from this 
group of bacteria. Despite the lack of reports, marine-derived counterparts have also 
demonstrated to be significant sources of active metabolites, both quantitatively and 
qualitatively. The number of active metabolites isolated from marine strains of actinomycetes 
is increasing considerably. In fact, it has been discovered that the aquatic species of 
actinomycetes produce not only the same compounds as their terrestrial counterparts [62], but 
also other types of compounds with unique structures and pharmacological activities. The 
search for new antitumor antibiotics from marine bacteria has led to the discovery of a wide 
range of pigmented cytotoxic compounds with different potency and selectivity, obtained 
from marine Streptomyces species found in different marine environments (Table 1.2). 
Varying not only in their appearance, but also in their chemical structures, these toxic 
compounds induce apoptosis in different ways, acting through various yet not fully 
understood pathways. These may include extrinsic pathways, through death receptor signaling, 
and intrinsic ones which involve multiple other intracellular signaling pathways. An example 
of this is streptochlorin, a yellowish crystalline solid isolated from marine Streptomyces sp. 
04DH110 (Fig.1.5 and Table 1.2, No.29) [63]. This compound was reported to activate 
caspases, upregulate the pro-apoptotic Bax and FasL, decrease the mitochondrial membrane 
potential, and increase the degradation of poly-(ADP-ribose)polymerase(PARP) and 
phospholipase C-γ1 proteins, while inhibiting the action of the anti-apoptotic Bcl-2 protein 
towards U937 leukemia cells [64]. Another examples are the blue and red colored 
ammosamides A and B isolated from the Streptomyces strain CNR-698 (Fig.1.5 and Table 1.2, 
No.2), which were reported to have pronounced selectivity against various cancer cell lines, 
with IC50 values ranging from 20 nM to 1 μM. In vitro cytotoxicity assay of both compounds 
against HCT-116 (HeLa) colon carcinoma cells produced an IC50 value of 320 nM. A 
preliminary investigation of their molecular mechanisms of action, carried out by converting 
them to highly conjugated fluorescent molecules, revealed that these compounds act on 
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proteins of the myosin family, which are responsible for numerous cell processes, including 
cell cycle regulation, cytokinesis, and cell migration [65]. There are dozens of other 
compounds isolated from marine actinomycetes whose anticancer activity mechanisms have 
yet to be determined (Table 1.2). It is interesting to note that the yellow colored 
N-carboxamido-staurosporine isolated from marine Streptomyces sp. QD518 has a more 
potent anticancer activity than its colorless analogs N-formyl-staurosporine and sesquiterpene 
(Fig.1.5 and Table 1.2, No.23). Exhibiting a mean IC50 value of 0.016 μg/mL and a mean IC70 
value of 0.17 μg/mL, this compound showed high tumor selectivity against 37 cancer cell 
lines from bladder, central nervous system, colon, gastric, head and neck, lung, mammary, 
ovarian, pancreatic, prostate, renal, skin, pleural mesothelium and uterine cancers [66]. 
However, the mechanism of action of this compound remains elusive. 
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Fig.1.5. Some pigmented compounds isolated from marine Streptomyces 
 
1.4.2. Cytotoxic pigments from marine Pseudoalteromonas 
The genus Pseudoalteromonas, solely belonging to a marine type of bacteria, has two kinds of 
species: pigmented and non-pigmented. According to some reports, the pigmented species are 
more effective than the non-pigmented species in terms of producing more potent biologically 
active compounds [67]. Holmström and co-workers reported that the pigmented species were 
more effective against biofouling than their non-pigmented counterparts [68, 69]. The 
pigmented strains seem to produce much stronger toxic secondary metabolites with a wide 
range of bioactivities, an essential requirement for drug development. Among these 
compounds, the ones with antitumor activities attract special interest. These compounds are 
discussed below and are also listed in Table 1.2. 
9H-pyrido[3,4-b]indole (norharman), a light yellow colored compound isolated from 
Pseudoalteromonas piscida, has been reported to have apoptotic effects (Fig. 1.6 and Table 
1.2, No.39). Although the exact molecular mechanisms of action are still elusive, the reported 
effects involved chromatin condensation and DNA degradation, which are characteristic of 
apoptosis [70]. 
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Fig.1.6. 9H-pyrido[3,4-b]indole (norharman) 
 
1.4.2.1. Prodiginines 
Red-pigmented prodigiosin compounds were first isolated from the ubiquitous bacterium 
Serratia marcescens and identified as secondary metabolites. The common aromatic chemical 
structure of these pigmented compounds was first named prodiginine by Gerber [71] (Fig.1.7). 
Prodigiosin was the first prodiginine for which the chemical structure was determined [72]. 
The name “prodigiosin” has been attributed to the isolation of prodigiosin from Bacillus 
prodigiosus bacterium (later renamed Serratia marcescens) [73], which was historically 
famed for the mysterious “bleeding bread” report [74, 75]. Prodiginines share a common 
pyrrolyldipyrromethene core structure and have a wide variety of biological properties, 
including antibacterial, antifungal, antimalarial, antibiotic, immunosuppressive, and 
anticancer activities [74, 76]. Such properties potentially make them one of the most powerful 
research tools in the past decade. 
There are many research reports and reviews regarding prodiginines and their biological 
activity investigations. In addition to the Serratia, several species of marine bacteria of the 
genera Streptomyces [73], Actinomadura [73], Pseudomonas [77], Pseudoalteromonas [42, 
48, 78–81], and others [82] have also been reported to produce prodigiosin and related 
compounds. In particular, Alteromonas denitrificans, which was isolated from the fjord 
systems off the west coast of Norway [80] and later reclassified as Pseudoalteromonas 
denitrificans [83], has been reported to produce cycloprodigiosin. This compound has 
immunosuppressive, antimalarial, and apoptosis-inducing activities [42-44]. Cycloprodigiosin 
demonstrated strong in vitro and in vivo apoptotic effects on liver cancer cell lines including 
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Huh-7, HCC-M, HCC-T (human hepatocellular carcinoma), HepG2 (human hepatoblastoma), 
dRLh-84 and H-35 (rat hepatocellular carcinoma) [42]. Suppressed cellular proliferation as a 
result of apoptosis was suggested to be due to the decrease of intracellular pH, caused by the 
uncoupling effect of cycloprodigiosin on proton transport by V-ATPase. The anti-apoptotic 
NF-κB protein activity responsible for DNA transcription was also reported to be suppressed 
by cycloprodigiosin [84]. Pseudoalteromonas rubra, found in the Mediterranean coastal 
waters [78], also produces cycloprodigiosin, in addition to prodigiosins [48, 79]. 
α-Proteobacteria isolated from a marine tunicate collected in Zamboanga, Philippines, was 
reported to produce heptylprodigiosin. In vitro antimalarial activity against Plasmodium 
falciparum 3D7 (IC50 = 0.068 mM and SI = 20) was about 20 times the in vitro cytotoxic 
activity against L5178Y mouse lymphocytes [45]. In vivo experiments using Plasmodium 
berghei-infected mice, at concentrations of 5mg/kg and 20mg/kg, significantly increased their 
survival, while also causing sclerotic lesions at the site of injection. Heptylprodigiosin, 
isolated from a marine α-proteobacterium, was reported to have in vitro cytotoxic activity 
against L5178Y mouse lymphocytes in addition to its antimalarial activity against 
Plasmodium falciparum 3D7 (Fig.1.7 and Table 1.2, No.47) [47]. This compound displayed 
synergistic effect with another cytotoxic compound, adociaquinone B, isolated from the 
marine sponge Xestospongia sp., against MCF-7 breast cancer cells [85]. A 3:1 ratio of 
adociaquinone B: heptylprodigiosin was the most effective, resulting in the greatest reduction 
of the IC50 values of the individual compounds, thus reducing the possible toxicity against 
normal cells. 
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Fig.1.7. Prodiginines and tambjamine 
The prodigiosin-like pigment PG-L-1, isolated from the bacterial strain MS-02-063 
belonging to γ-proteobacterium, was reported to have a strong cytotoxic effect against MDCK, 
CHO, HeLa, Vero, XC, and PtK1 cells [86]. PG-L-1 also induced apoptosis of U937 cells, 
accompanied by the increase of intracellular pH, activation of p38 MAP kinase, inhibition of 
O2- generation and DNA fragmentation. The apoptosis mechanisms of PG-L-1 may be 
attributed to the increase of intracellular pH and the activation of p38 MAP kinase [86]. 
Biologically active components of the marine Pseudoalteromonas tunicata have been 
identified as alkaloid tambjamines, the chemical structures of which are partly similar to 
prodiginines (Fig.1.7 and Table 1.2, No.37) [51]. Screening of the biological activities of 
some tambjamines against certain human cancer cell lines has revealed that they possess 
moderate antitumor activity compared to the doxorubicin control [52]. 
Other bacteria reported to produce red pigments include Hahella [87], Vibrio [88], 
22 
  
Zooshikella [89], and Pseudoalteromonas [81], isolated from the coasts of Korea, Taiwan, 
and Japan. Kim et al. [47] identified red-pigmented prodiginines from Hahella chejuensis. 
Nakashima et al. also evaluated the biological activity of similar prodiginines from a 
bacterium assumed to belong to the genus Hahella [90]. Red pigment-producing bacterial 
species have further been isolated from river water [91, 92] and even from a swimming pool 
[93]. The most active prodiginine derivatives have already entered clinical trials as potential 
drugs against different cancer types [74]. 
Prodiginines were reported to have anticancer activity against nearly 60 human cancer 
cell lines with little or no effect on normal cells [78, 94]. In fact, these compounds were 
proved to induce apoptosis even in drug-resistant tumor cells, thus being able to overcome 
one of the main problems in chemotherapy. Synthetic prodiginine derivatives such as 
PNU156804 and GX15-070 have already entered clinical trials to develop 
immunosuppressive and anticancer drugs, respectively [78]. Although advanced studies have 
been conducted on these compounds to determine their molecular mechanisms of cytotoxicity, 
information regarding the way they induce apoptosis remains elusive because of their 
extremely wide cellular targets (Fig.1.8). Despite the lack of information regarding the 
cytotoxicity mechanisms of prodiginines, four main possible pathways leading to apoptosis of 
cancer cells have been proposed: (1) Regulation of intracellular pH by proton pumping 
ATPases [95], (2) Arrest of cell cycle at different levels of G- or S-stages by inhibition of 
protein activities promoting cell differentiation and proliferation [80, 96, 97], (3) Copper 
(II)-mediated DNA fragmentation [98], and (4) Regulation of signal transduction pathway 
molecules [99, 100]. 
Prodigiosin has also demonstrated antimetastatic activity against 95-D human lung 
carcinoma and B16BL6 mouse melanoma cells by inhibiting their migration and invasion, 
both in vitro and in vivo. The action of prodigiosin is dose-dependent, reaching 50% 
metastasis inhibition of 95-D cells at 4.66 μM for 12 h [101]. These findings indicate that 
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prodigiosin-like compounds are potential chemotherapeutic drug candidates against cancer. 
 
 
Fig.1.8. Possible cellular targets of prodiginines leading to apoptosis. 
The figure shows intrinsic (mitochondrial) and extrinsic pathways that participate in the 
apoptotic process by prodiginines. These two pathways, comprising four main mechanisms, 
are suggested to induce apoptosis by prodiginines in the following way: (1) Regulation of 
intracellular pH by proton pumping ATPases, (2) Arrest of cell cycle at different levels of G- 
or S-stages by inhibition of protein activities promoting cell differentiation and proliferation, 
(3) Copper (II)-mediated DNA fragmentation, (4) Regulation of signal transduction pathway 
molecules. 
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Table 1.2. Antitumor pigments isolated from marine bacteria. 
No Compound Appearance Structural class Source Active against 
(cell lines) 
Effective 
dose 
Reference 
Actinomycetes 
1. Actinofuranones A & B Yellow oils Polyketide Streptomyces sp. 
CNQ766 
Mouse 
splenocyte 
T-cells and 
macrophages 
IC50: 20 
μg/mL 
[102] 
2. Ammosamides A & B Blue & red solids Pyrroloiminoquinone Streptomyces sp. 
CNR-698 
HCT-116 
(colorectal 
carcinoma), 
HeLa 
IC50: 0.02~1 
μM 
[65] 
3. Arcyriaflavin A Orange crystal Indolocarbazole Marine 
actinomycete 
Z2039-2 
K562 
(leukemia) 
IC50: 100 μM [103] 
4. Butenolides Yellow syrup Butenolide Streptoverticillium 
luteoverticillatum 
K562; 
 
 
P388 
(leukemia) 
IC50: 8.73, 
6.29, 1.05 
μmol/mL; 
0.34, 0.19, 
0.18 
μmol/mL 
[104] 
5. Chandrananimycins A, B, C Orange solid Phenoxazinone Actinomadura sp. 
M048 
CCL HT29 
(colon 
carcinoma), 
IC70: <1.4 
μg/mL 
[105] 
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MEXF 514L 
(melanoma), 
and others 
6. Chartreusin Yellow solid Polyketide Streptomyces sp. 
QD518 
L1210 
(leukemia), 
B16 
(melanoma) 
Not 
mentioned 
[66, 106] 
7. Chinikomycin A Yellowish-brown 
solid 
Polyketide Streptomyces sp. 
M045 
MAXF 401NL 
(mammary 
cancer), RXF 
944L (renal 
cancer), and 
others 
IC50: 
2.41, 
 
4.02 
μg/mL 
[26] 
8. Chinikomycin B Red solid Polyketide Streptomyces sp. 
M045 
MAXF 401NL IC50: 
3.04, 
μg/mL 
[26] 
9. Chlorinated dihydroquinones Pale yellow 
crystals 
Terpenoid 
dihydroquinones 
Streptomyces sp. 
CNQ-525 
HCT-116 IC50: 
0.97~2.40 
μg/mL 
[107] 
10. Daryamides A-C Yellow powder Polyketide Streptomyces sp. 
CNQ-085 
HCT-116 IC50: 
3.15~10.03 
μg/mL 
[108] 
11. Gutingimycin Yellow Polyketide Streptomyces sp. 
B8652 
Not mentioned IC70: 3.4 
μg/mL 
[109] 
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12. IB-00208 Orange Polyketide Actinomadura sp. 
BL-42-PO13-046 
P-388, A-549 
(lung 
carcinoma), 
HT-29 
(colon cancer), 
SK-MEL-28 
(melanoma) 
MIC: 1 nM [110] 
13. Iodinin Violet solid Phenazine Actinomadura sp. 
M048 
MAXF 401NL, 
RXF 944L, and 
others 
IC50: 3.6 
μg/mL 
[105] 
14. Questiomycin A Orange solid Phenoxazinone Actinomadura sp. 
M048 
CCL HT29, 
MEXF 514L, 
and others 
IC70: <1.4 
μg/mL 
[105] 
15. K252c Yellow crystal Indolocarbazole Marine 
actinomycete 
Z2039-2 
K562 IC50: 10 μM [103] 
16. Lajollamycin Yellow solid Mixed 
polyketide/non-riboso
mal peptide 
Streptomyces 
nodosus 
(NPS007994) 
B16-F10 
(melanoma) 
EC50: 9.6 μM [111] 
17. Lomaiviticins A and B Amorphous red 
powder 
Diazobenzofluorene 
glycosides 
Micromonospora 
lomaivitiensis 
A panel of 
cancer cells 
IC50: 0.01~98 
ng/mL 
[112] 
18. Lucentamycins A & B Yellow oil Peptides Nocardiopsis 
lucentensis 
(CNR-712) 
HCT-116 IC50: 
0.20, 11 μM 
[113] 
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19. Manumycin A Yellow solid Polyketide Streptomyces sp. 
M045 
L-1210 IC50: 3.1 
μg/mL 
[26, 114] 
20. Marinomycins A-D Yellow powder Polyketide Marine 
actinomycete 
Marinispora 
CNQ-140 
NCI’s 60 
cancer 
cell line panel 
LC50: 0.2~2.7 
μM 
[115] 
21. Marmycin A Red crystalline 
solid 
Polyketide Streptomyces sp. HCT-116; 
12 other cancer 
cells 
IC50: 0.06 
μM; 
0.022 μM 
[116] 
22. Marmycin B Pink crystalline 
solid 
Polyketide Streptomyces sp. HCT-116; 
12 other cancer 
cells 
IC50: 1.09 
μM; 
3.5 μM 
[116] 
23. N-carboxamido-staurosporine Yellow solid Indolocarbazole Streptomyces sp. 
QD518 
37 cancer cells IC50: 0.016 
μg/mL; 
IC70: 0.17 
μg/mL 
[66] 
24. Parimycin Orange solid Polyketide Streptomyces sp. 
B8652 
GXF 251L 
(gastric 
cancer), H460 
(lung cancer), 
and others 
IC70: 
0.9~6.7 
μg/mL 
[117] 
25. Piericidins C7 & C8 Yellow Polyketide Streptomyces sp. 
YM14-060 
Rat glial cells; 
mouse Neuro-2a 
cells 
IC50: 1.5, 0.45 
nM; 
0.83, 0.21 nM
[118] 
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(neuroblastoma)
26. Resistoflavine Yellow solid Polyketide Streptomyces 
chibaensis AUBN1/7
HMO2 (gastric 
adenocarcinom
a) 
 
 
 
HePG2 
(hepatic 
carcinoma) 
GI50: 0.007 
μg/mL; 
TGI: 0.009 
μg/mL; 
LC50: 
0.013 μg/mL
GI50: 0.010 
μg/mL; 
TGI: 0.013 
μg/mL; 
LC50: 
0.016 μg/mL
[119] 
27. Resistomycin Yellow solid Polyketide Streptomyces sp. 
B8005, 
Streptomyces sp. 
B4842, 
MCF-7 (breast 
cancer), 
UACC-62 
(melanoma), 
and others 
 
>50 ng/mL 
[120, 121] 
28. SS-228 Y Yellowish-brown 
powder 
Polyketide Chainia sp. SS-228 Ehrlich ascites 
tumor cells 
LD50: 
1.56~6.25 
mg/kg 
[122] 
29. Streptochlorin Yellow crystalline 
solid 
Indole Streptomyces sp. 
04DH110 
U937 
(leukemia) 
IC50: 10~12 
μg/mL 
[64, 123] 
30. Tetracenomycin D Yellow-orange Polyketide Streptomyces sp. L1210 IC50: 22.1 μM [120, 124] 
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solid B8005 
31. Thiocoraline Pale yellow 
crystalline 
Cyclic 
thiodepsipeptide 
Micromonospora sp. 
L-13-ACM2-092 
P388, A549, 
HT-29, 
MEL-28 
(melanoma) 
IC50: 
0.002~0.01 
μg/mL 
[125, 126] 
32. Trioxacarcins A-D Yellow solid Polyketide Streptomyces sp. 
B8652 
HT-29, 
MEXF 514L, 
and others 
IC70: 
0.001~2.161 
μg/mL 
[127] 
33. 1-Hydroxy-1-norresistomycin Pale yellow solid Polyketide Streptomyces 
chibaensis AUBN1/7
HMO2, 
 
 
 
 
 
HePG2 
GI50: 0.009 
μg/mL; 
TGI50: 0.012 
μg/mL; 
LC50: 0.015 
μg/mL 
GI50: 0.014 
μg/mL; 
TGI50: 0.018 
μg/mL; 
LC50: 0.021 
μg/mL 
[128] 
34. 1,6-Phenazinediol Yellow solid Phenazine Actinomadura sp. 
M048 
LXFA 629L, 
LXFL 529L, 
(lung 
carcinoma), 
IC50: 3.2 
μg/mL 
[105] 
30 
  
and others 
Pseudoalteromonas 
35. Cycloprodigiosin Red solid Pyrrole alkaloid Pseudoalteromonas 
denitrificans 
6 liver cancer 
cell lines 
IC50: 
276~592 
nmol/L 
[42] 
36. Prodigiosin Red solid Pyrrole alkaloid Streptomyces, 
Pseudomonas, 
Pseudoalteromonas, 
Actinomadura sp. 
Standard 60 
human tumor 
cell line panel 
GIC50: 0.014 
μM; 
LC50: 2.1 μM
[94] 
37. Tambjamines Yellow oil Alkaloid Pseudoalteromonas 
tunicata 
HL60 
(leukemia), 
MDA-MB435 
(breast 
carcinoma), 
HCT-8 
(colorectal 
carcinoma), 
and others 
IC50: 
0.23~3.42 
μg/mL 
[51, 52] 
38. Violacein Purple solid Indolocarbazole Pseudoalteromonas 
tunicata 
Pseudoalteromonas 
sp. 520P1 
Collimonas CT 
U937, K562, 
and others 
IC50: 0.5~1 
μM 
[129, 130] 
39. 9H-pyrido[3,4-b]indole Light yellow β-Carboline alkaloid Pseudoalteromonas HeLa, IC50: 5 μg/mL [70] 
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(Norharman) crystalline piscida BGC-823 
(stomach 
cancer) 
Cyanobacteria 
40. Curacin D Pale yellow oil Lipid Lyngbya majuscula MCF-7 IC50: 0.34 μM [131] 
41. Hectochlorin Pale yellow solid Lipopeptide Lyngbya majuscula 60 cancer cell 
lines 
GI50: 5.1 μM [132] 
42. Homodolastatin 16 Pale yellow oil Cyclic depsipeptide Lyngbya majuscula WHCO1 and 
WHCO6 
(esophageal 
cancer); 
ME180 
(cervical 
cancer) 
IC50: 4.3 and 
10.1 μg/mL; 
8.3 μg/mL 
[133] 
43. Jamaicamides A, B and C Pale yellow oils Mixed 
polyketide-peptide 
Lyngbya majuscula NCL-H460 
(lung cancer) 
and Neuro-2a 
LC50: 15 μM [134] 
44. Lyngbyabellin B Pale yellow oil Cyclic depsipeptide Lyngbya majuscula KB (epidermal 
carcinoma) 
IC50: 0.1 μM [135] 
45. Phycocyanin Light blue Phycobiliprotein Spirulina platensis K562, Hep3B 
(hepatoma) 
IC50: 50 μM [136] 
Other bacteria 
46. Alteramide A Yellow powder Alkaloid Alteromonas sp. P388, L1210, 
KB  
IC50: 0.1, 1.7, 
5.0 
[137] 
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μg/mL 
47. Heptylprodigiosin Red solid Pyrrole alkaloid Pseudovibrio 
denitrificans Z143-1
L5178Y 
(lymphoma) 
IC50: 0.677 
μM 
[85] 
48. PG-L-1 Red solid Prodigiosin-like 
Pyrrole alkaloid 
γ-Proteobacterium 
MS-02-063 
U937, CHO, 
HeLa, and 
others 
ED50: 
70~150 
ng/mL 
[86] 
49. Unknown phenazine 
derivatives 
Yellow needles Phenazine Bacillus sp. P388; 
K562 
IC50: <50 μM;
74, 87 μM 
[19] 
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1.4.2.2. Violacein 
Another pigment that has prominent biological properties, including anticancer activity, is a 
purple colored violacein (Fig. 1.8 and Table 1.2, No.38). This compound is a well-known 
indole derivative also known as 3-(1,2-dihydro-5-(5-hydroxy-1H-indol-3-yl)-2-oxo-3H- 
pyrrol-3-ilydene)-1,3-dihydro-2H-indol-2-one. The violet pigment violacein is an indole 
derivative, predominantly isolated from bacteria of the genus Chromobacterium that inhabit 
the soil and water of tropical and subtropical areas [138]. Over the past decade, the 
biosynthesis and biological activities of violacein have been extensively studied, and many 
scientific papers and reviews have been published [139-143]. Violacein has a variety of 
biological activities, including antiviral, antibacterial, antiulcerogenic, antileishmanial, and 
anticancer properties [138, 139, 143, 144]. Use of violacein as a chemical defense against 
eukaryotic predators has also been investigated [53, 145-147]. 
Despite unique antibiotic properties, the anticancer activity of violacein has attracted 
special attention, and many studies have been recently conducted to understand its apoptotic 
mechanisms. 
One of the first published reports on violacein production by marine bacteria was by 
Hamilton and Austin [148]. This bacterial strain, Chromobacterium marinum, was isolated 
from open ocean waters and produced a blue pigment that was identified as violacein on the 
basis of physicochemical characteristics [148]. Later, Gauthier [50] described 16 
violet-pigmented heterotrophic bacilli isolated from Mediterranean coastal waters and 
proposed the name Alteromonas luteoviolaceus for these strains. Another six bacterial species 
were also isolated by Gauthier et al. [149] from neritic waters on the French Mediterranean 
coast and were very similar to Alteromonas species. These species produced characteristic 
pigmentations ranging from pinkish beige with reddish-brown diffusible pigment, lemon 
yellow, bright red turning carmine in old cultures, and orange to greenish-brown. Light violet, 
dark violet, or almost black pigments were also produced and later identified as violacein. The 
34 
  
strains showed antibiotic activity against Staphylococcus aureus [149]. Subsequently, many 
other reports on violacein production have been published [54, 55]. 
Several purple pigment-producing Alteromonas species were also isolated from Kinko 
Bay in Kagoshima Prefecture, Japan. One of these, Alteromonas luteoviolacea (reclassified as 
Pseudoalteromonas luteoviolacea), is the only extensively characterized marine bacterium 
ever reported that produces violacein [50-52]. 
Investigations on the molecular mechanisms of cytotoxicity of violacein isolated from 
Chromobacterium violaceum, revealed the activation of caspase-8 and p38 MAP kinase, as 
well as the transcription of NF-κB target genes in HL60 leukemia cells [129]. The IC50 value 
of violacein against HL60 cells was determined to be 700 nM. In addition to activation of the 
TNF receptor, upregulation of the expression of p21 protein, activation of caspase-3, 
phosphatidylserine exposure, fragmentation of poly (ADP-ribose) polymerase (PARP), 
decrease of c-jun expression, and downregulation of the inhibitor of apoptosis protein 1 
(IAP1), all leading to facilitate the apoptosis process, were also observed [129]. In another 
study by the same research group, violacein-induced apoptosis of four colon cancer cell lines 
was associated with cell cycle blockage at the G1 phase, upregulating the levels of p53, p27 
and p21 proteins and decreasing the expression of cyclin D1 [130]. However, the main cause 
of apoptosis was attributed to the inhibition of Akt (PKB) phosphorylation, which changed the 
levels of the proteins mentioned above, with subsequent activation of the apoptotic pathway 
and downregulation of NF-κB signaling. This signaling pathway in colon cancer cells was 
suggested to be more sensitive to 5- fluorouracil (5-FU), a potent chemotherapeutic agent, in a 
synergistic fashion with violacein. The elevated levels of the pro-apoptotic Bad protein were 
thought to be promoted by the activation of caspase-3, in addition to the activation of 
caspases-8 and -9, and the decreased level of FADD was suggested to be indicative of the 
exclusion of the extrinsic apoptotic pathway [130]. 
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Fig.1.8. Violacein and deoxyviolacein. 
 
1.4.3. Cytotoxic pigments from marine cyanobacteria 
Marine cyanobacteria, previously known as blue-green algae, are also productive 
microorganisms which have been known for their ability to produce a wide variety of unique 
secondary metabolites. Although, more than 300 structurally diverse biomolecules have been 
obtained from marine cyanobacteria, they are especially famous for the production of 
lipopeptides and depsipeptides [150], most of which are biologically active. A number of 
these bioactive compounds have demonstrated anticancer activity, with different potency 
against various cancer cell lines (Table 1.2). It should be noted that many well-known potent 
antitumor compounds (e.g., dolastatin), previously believed to originate from marine 
invertebrate species such as sea hares and mollusks, have recently be found to actually 
originate from marine cyanobacteria living in symbiosis with those species. 
Phycocyanin, a pigment produced by the cyanobacterium Spirulina platensis [151], 
belongs to the light-harvesting phycobiliprotein family and is used as a fluorescent agent in 
immunoassay analysis [152]. Phycocyanin has a characteristic light blue color, absorbs 
orange and red light near 620 nm, and emits fluorescence at about 650 nm. Being an 
accessory pigment that works in conjunction with chlorophyll a, it is also a well-known 
natural food colorant. In addition to its anti-oxidative and anti-inflammatory effects, 
phycocyanin was also found to have cytotoxicity against cancer cells, the molecular 
mechanisms of which displayed characteristic features of apoptosis, such as cell shrinkage, 
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membrane blebbing and nuclear condensation followed by mitochondrial cytochrome c 
release, PARP cleavage and downregulation of the anti-apoptotic Bcl-2 protein (Table 1.2, 
No.45) [136]. 
Nevertheless, not only pigmented compounds show bioactivities. There are also a 
number of non-pigmented, highly potent cyanobacterial active metabolites with antitumor 
activity against various cancer cell lines, isolated from different species, representing potential 
candidates for future drug development. It is expected that more compounds with interesting 
biological activities will be discovered in the future, since this family of bacteria remains 
virtually uninvestigated. Therefore, researchers specializing in chemistry, biology, 
pharmacology and medicine have a challenging task to accomplish in the study of bioactive 
compounds from marine microorganisms. 
 
1.5. Biosynthesis of pigments 
Numerous reports detail the regulation and biosynthesis of bacterial secondary metabolites. 
Increased research and verification of specific bacterial pathways has predominantly been due 
to the antibiotic, immunosuppressive, and anticancer potential of these compounds. A brief 
discussion of this topic is given next, as detailed information is further provided in the cited 
references. 
Biosynthesis of bacterial prodiginines has extensively been studied and reviewed [153, 
154]. Prodigiosin biosynthesis was proposed to originate during the enzymatic condensation 
of 2-methyl-3-n-amyl-pyrrole (MAP) and 4-methoxy-2,2'-bipyrrole-5-carbaldehyde (MBC) 
precursors. Prodiginine biosynthetic gene clusters for Serratia sp. ATCC 39006 [155], 
Serratia marcescens ATCC 274 [155], Hahella chejuensis KCTC 2396 [47, 156], and 
Streptomyces coelicolor A3(2) [157] have been identified, sequenced, and expressed. Several 
gene clusters are involved in the biosynthetic pathway, depicted as pig in Serratia strains, red 
in S. coelicolor A3(2), and hap (numbered) in H. chejuensis KCTC 2396, with each encoding 
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several proteins responsible for synthesis. The largest gene cluster found in S. coelicolor 
A3(2) consists of four transcriptional units, whereas the other three clusters are strongly 
homologous to each other and are arranged unidirectionally. 
In Serratia strains, pigB–pigE genes were identified to encode proteins responsible for 
the biosynthesis of MAP and condensation with MBC to form prodigiosin [153, 154]. A 
common pathway of MBC biosynthesis is proposed for all strains, in which proline, acetate, 
serine, and S-adenosylmethionine are incorporated into the bipyrrole at the initial stage [154]. 
PigA, PigF, PigG, PigH, PigI, PigJ, PigM, and PigN in Serratia strains and RedE, RedI, 
RedM, RedN, RedO, RedW, RedV, and RedX proteins in S. coelicolor A3(2) have been 
determined to participate in MBC biosynthesis [154]. PigB, PigD, and PigE enzymes in 
Serratia strains were proposed to be involved in the MAP biosynthesis, which requires 
2-octenal as the initial precursor [154]. Monopyrroles condense with MBC during the final 
step of prodigiosin and/or undecylprodigiosin biosynthesis. PigC and its homologues catalyze 
this condensation in bacteria. 
Some prodiginines can also be produced when monopyrroles are supplied to colorless S. 
marcescens mutants [73]. Addition of monopyrroles directly to a culture medium or as a 
vapor across the culture surface of a colorless mutant of S. marcescens resulted in the strain 
becoming initially pink and later red, indicating prodiginine formation [73]. Similar 
prodiginine biosynthesis produced by exogenously adding MAP and MBC was observed in 
white strains of Serratia marcescens isolated from patients [158]. 
The violacein biosynthesis pathway and associated biosynthetic enzymes have been 
extensively studied [140, 142, 159], although certain reactions and intermediates are yet to be 
elucidated. Currently, this proposed system involves an operon of five genes, vioA–vioE, 
which are transcriptionally regulated by a quorum-sensing mechanism that uses 
acylhomoserine lactones as autoinducers. At the early stationary phase of bacterial growth, 
acylhomoserine lactones accumulate in the culture medium, inducing the transcription of the 
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vio genes. Therefore, violacein is considered a typical secondary metabolite in bacteria. The 
first enzyme encoded by the vio gene operon, VioA, converts L-tryptophan to 
indole-3-pyruvic acid imine (IPA imine), and the second enzyme, VioB, catalyzes the 
reaction to convert IPA imine into an unidentified compound X (possibly an IPA imine 
dimer) [160, 161]. Compound X then undergoes successive reactions, catalyzed by the 
enzymes VioE, VioD, and VioC, to produce violacein. 
Phenazine pigment biosynthesis reportedly involves shikimic acid as a precursor and 
forms chorismic acid as an intermediate product. Two molecules of chorismic acid then form 
phenazine-1,6-dicarboxylic acid, which is sequentially modified to create a variety of 
phenazine derivatives with different biological activities [162]. Pseudomonas aeruginosa 
PAO1 has two gene clusters (phzA1B1C1D1E1F1G1 and phzA2B2C2D2E2F2G2), with each 
cluster capable of producing phenazine-1-carboxylic acid (PCA) from chorismic acid [163]. It 
is proposed that PhzM and PhzS catalyze the subsequent conversion of PCA to pyocyanin. In 
addition, PhzH is responsible for producing phenazine-1-carboxamide from PCA. 
Fridamycin, hymalomycin, and chinikomycin are typical bacterial compounds that share 
a quinone skeleton. However, little information regarding the biosynthesis of these 
compounds has been accumulated. 
Detection and identification of the entire P. tunicata gene cluster involved in the 
biosynthetic pathway production of the tambjamine YP1 using recombinant E. coli was 
conducted by Australian researchers Burke et al. [164]. In total, 19 proteins encoded the Tam 
cluster participate in the postulated biosynthetic pathway. Among them, 12 were found to 
have high sequence similarity to the red proteins responsible for undecylprodigiosin synthesis 
in S. coelicolor A3(2) and the pig proteins involved in prodigiosin biosynthesis in Serratia sp. 
[164]. Such similarity in the chemical structures of these two classes of compounds results in 
tambjamines having two pyrrole rings while the prodiginines have three. As is the case for the 
prodiginines, 4-methoxy-2,2-bipyrrole-5-carbaldehyde (MBC) is initially formed from proline, 
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serine, and malonyl CoA in the tambjamine biosynthetic pathway. A double bond is inserted 
by TamT and an amino group is transferred by TamH to dodecenoic acid activated by AfaA, 
which is predicted to be an acyl-CoA synthase. The resulting dodec-3-en-1-amine is 
condensed with MBC by TamQ to form tambjamine YP1 [164]. 
In addition to V. cholera, S. colwelliana, A. nigrifaciens, and C. tyrosinoxydans, melanin 
syntheses have also been reported in M. mediterranea, which contains the tyrosinase gene 
operon [165], and in an epiphytic Saccharophagus degradans 2-40 bacterium [166]. While 
the specific details of melanin formation continue to be debated, well-defined biosynthetic 
schemes have now been proposed. Two different biosynthetic pathways synthesize the 
eumelanins and pheomelanins. Both pathways are initiated by the oxidation of L-tyrosine to 
3,4-dihydroxyphenylalanine (DOPA) and the subsequent creation of dopaquinone by 
tyrosinase. The latter product is transformed either to pheomelanin by combining with cystein 
and forming an intermediate S-cysteinyldopa and benzothiazine or to eumelanin with 
intermediate leucodopachrome, dopachrome (red), 5,6-dihydroxyindole, 5,6-indolequinone 
(yellow) formation [24]. 
Nostoc punctiforme ATCC 29133 is the only scytonemin producing organism whose 
genome has been fully sequenced [167]. This scytonemin biosynthesis potentially involves a 
gene cluster consisting of 18 open reading frames (ORFs) (NpR1276 to NpR1259). Although, 
the functional roles of all these ORFs are not yet fully determined, some intriguing 
hypotheses have been proposed. In particular, both tyrosine and tryptophan are implicated as 
biosynthetic precursors for scytonemin in the pigment formation pathway. NpR1275, which 
functionally resembles leucine dehydrogenase, is utilized in the early stages of scytonemin 
synthesis in N. punctiforme, thereby oxidizing tryptophan and/or tyrosine to their 
corresponding pyruvic acid derivative. 
Alternatively, it is suggested that NpR1269, a putative prephenate dehydrogenase, 
generates p-hydroxyphenylpyruvic acid, which is a derivative of tyrosine in the early pathway 
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stages. NpR1276 uses two pyruvic acid derivatives from tryptophan and tyrosine for the 
synthesis of a labile β-ketoacid product, which is homologous to the thiamin diphosphate- 
(ThDP-) dependent enzyme acetolactate synthase. NpR1274 possibly catalyzes the 
intermediate cyclization and decarboxylation of the β-ketoacid product to form the 
indole-fused cyclopentane moiety of the pigment [168]. Monomer precursors that are formed 
then undergo dimerization to produce scytonemin. NpR1263, which was found to be similar 
to a tyrosinase in melanin biosynthesis, participates in these later oxidative dimerization steps, 
thereby forming scytonemin [169]. Functional roles of other ORFs and their putative 
intermediate products for the pigment production are still under investigation. 
 
1.6. Concerns regarding the physiological role of pigmented compounds 
A number of bacterial species, including those inhabiting the vast marine environment, 
produce a wide variety of pigments that are important to cellular physiology and survival. 
Many of these natural metabolites were found to have antibiotic, anticancer, and 
immunosuppressive activities. These secondary metabolites, produced by microorganisms 
mostly via the quorum sensing mechanism, have the ability to inhibit the growth of or even 
kill bacteria and other microorganisms at very low concentrations. Due to such diverse and 
promising activities against different kinds of diseases, these compounds can play an 
important role in both pharmaceutical and agricultural research. 
It still remains uncertain why these pigmented secondary metabolites from bacteria have 
antibiotic and/or cytotoxic activities. Although, their true physiological role is yet to be fully 
discovered, there are a few reports that provide reasonable explanations by making 
comparisons with nonpigmented bacteria. In particular, the relationships between pigment 
production and toxicity have been studied by Holmström et al. [72], who found that 90% of 
all dark-pigmented compounds taken from marine living surfaces showed inhibitory activity 
towards invertebrate larvae. Two fractions isolated after column chromatography, one 
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colorless and the other a yellowish-green color, were identified as phenazine derivatives from 
unidentified marine Streptomycete sp. by Pusecker et al. [20]. The colorless fraction was 
biologically inactive, while the pigmented phenazine derivative showed highly active 
antibiotic properties. Previous studies have also demonstrated that marine bacterial 
metabolites with antibiotic properties were always pigmented [170]. Screening of 38 
antibiotic-producing bacterial strains revealed that all pigmented bacteria belonging to the 
Pseudomonas-Alteromonas group displayed antibiotic activity, while nonpigmented bacteria 
were inactive. 
Considering data from all reported literature, a number of reasonable biological functions 
for pigment production in bacteria have been established. In general, the pigmented marine 
isolates seem to play two important roles: firstly, they provide an adaption to environmental 
conditions, and, secondly, they provide defense against predators [171]. For instance, it has 
been shown that the brown colored melanin pigments produced by a variety of species, as 
well as a yellow green colored scytonemin pigment isolated from cyanobacteria, protect cells 
from UV irradiation and desiccation [24, 39]. Therefore, in order to adapt to the excessive 
sunlight and survive under harmful UV irradiation, bacteria must produce these indispensable 
compounds. Griffiths et al. [172] found that carotenoids, which were later suggested to be a 
substitute for sterols, are an important structural component of microbial membranes [173] 
and may protect bacterial cells from photooxidation or damage caused by visible light 
irradiation. 
Several bacterial pigments that act as antagonists by exhibiting antibiotic activity against 
other organisms can be considered as potent weapons for survival and effective chemical 
defenses against eukaryotic predators. This class of bioactive agents includes almost all 
pigmented compounds commonly produced by Pseudoalteromonas, Pseudomonas, and 
Streptomyces species. These compounds inhibit the settlement of marine invertebrate larvae 
[174], the germination of algal spores [175] and protect the host surface by interfering with 
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bacterial colonization and biofilm formation [176]. They may also inhibit other organisms 
that compete for space and nutrients. 
Such hypotheses are also supported by a number of studies that found that these bacterial 
compounds were active against other prokaryotes and even eukaryotes [177-185]. In many 
studies, pigmented bacterial strains demonstrated a strong and broad range of antibiotic 
activities against other organisms, while nonpigmented strains did not [176, 186]. A clear 
correlation between pigment production and antibacterial activities of the two Silicibacter sp. 
strain TM1040 and Phaeobacter strain 27-4 grown under static conditions was further 
reported by Bruhn et al. [186]. Mutant strains, which lacked pigment production, also lost 
their biological activities. Holmström et al. have also shown a close relationship between 
pigmentation and inhibitory activity, whereby 20 out of 22 dark pigmented bacterial strains 
tested displayed inhibitory activity against the settlement of two invertebrate larvae and algal 
spores [72]. 
Amongst other bacterial strains, Pseudoalteromonas has the most diverse antibiotic 
activities against alga biofouling, and the dark green pigmented P. tunicata exhibits the most 
active and broadest range of inhibitory activity when compared to other strains from this 
genus [176]. Two nonpigmented P. nigrifaciens and P. haloplanktis strains were also found 
not to display any antibiotic activities using various bioassays [176]. 
Blue-pigmented pyocyanin production in P. aeruginosa (Pup14B) was observed by 
Angell et al. to be induced by Enterobacter species (Pup14A and KM1), and this pyocyanin 
displayed moderate antibiotic activity against E. coli and yeast [187]. It was experimentally 
demonstrated that metabolites produced by Pup14A strain are necessary for the production of 
this pigment in Pup14B strain [187]. Many other reports describe synergism between bacteria 
and higher organisms; however, this is a rare example between two bacterial species [188]. 
Such an unusual case contrasts with the hypothesis of the regulated biodiversity of marine 
bacteria, in which surface-associated microorganisms produce antimicrobial agents [176] to 
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prevent competing microorganisms. The symbiosis of the two bacterial species is not yet fully 
understood, although both species appear to benefit from the pigment production. 
One of the promising biological activities of marine bacteria isolates is their cytotoxic 
effect against cancer cells. Despite many investigations, the exact molecular mechanism of 
this pigmented compound cytotoxicity remains undetermined and requires further study. For 
example, violacein is known to cause apoptosis in tumorous cells [143]. However, the 
pathways leading to cell death have not yet been linked to the possible effects of the pigment, 
which was also shown to affect signal transduction agents, such as protein kinase and protein 
phosphatase family enzymes that play crucial role in cell differentiation and proliferation. 
In a study by Bromberg et al., violacein showed inhibitory activity against protein 
phosphatases isolated from human lymphocytes [189]. A similar study was also conducted by 
Fürstner et al. to assess the inhibitory activity of prodigiosin derivatives [111]. Other targets 
of these compounds, including ion channels, are further being investigated [105, 190-192]. 
Unexpected problems have also arisen when investigating marine environments. While 
the marine environment is a promising source for identifying microorganisms that can 
produce important biologically active pigments, yields of these compounds remain variable 
and are sometimes too low to provide enough material for drug development [193] or 
commercial applications. The main reason for such low yields is that these compounds are 
secondary metabolites and production depends on the quorum sensing mechanism. 
Despite marine bacteria being capable of growing in the extremely low concentrations of 
nutrients that often exist in seawater, most species still require seawater or its equivalent as a 
growth medium for artificial culturing. Seawater is therefore used for the growth of marine 
bacteria, or similar levels of sodium, potassium, and magnesium chloride are supplemented in 
cultures. Optimal growth and the production of pigments are only sustained for most bacteria 
when appropriate salt mixtures are used for culturing, as is the case for the 
prodigiosin-producing marine Pseudomonas magnesiorubra and Vibrio psychroerythrus, 
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among other marine species. These bacteria grew optimally and produced red pigment when 
cultured in seawater or its equivalent, while pigment production by the terrestrial Serratia 
marcescens was inhibited in 3% sea salts [73]. 
Enhancing low pigment productivity is one of the main issues facing researchers, and 
some solutions have already been reported. It is well established that antibiotic production by 
bacteria might be regulated both qualitatively and quantitatively by the nature of the culture 
medium. In particular, the addition of individual natural compounds to nutrient media or the 
use of gene expression methods was found to increase the pigment production far beyond 
expectations. For example, saturated fatty acids, especially peanut broth, was found to be a 
better choice in increasing prodigiosin production by 40-fold (approximately ~39 mg/mL) in 
S. marcescens [194]. 
Undecylprodigiosin synthesis by S. marcescens was also markedly enhanced by the 
addition of vegetable (soybean, olive, and sunflower) oils (2–6% [v/v]) and amino acids to the 
fermentation broth [195, 196]. Violacein production by the recombinant Citrobacter freundii 
strain, the genes of which were reconstructed from Duganella sp. B2, reached up to 1.68 g/L, 
making it fourfold higher than the highest production previously reported [197]. It is 
anticipated that these methods will facilitate the production of sufficient quantities of many 
bioactive and pharmacologically important compounds obtained from bacteria of marine 
origin. These compounds, including prodiginine and violacein, are now considered as 
potential drug candidates for potentially fatal diseases such as cancer and malaria. Although 
further improvement of culture methods and technologies for pigment production including 
recombinant technology is necessary, bioactive compounds from marine bacteria may 
potentially replace the existing drugs that have lower therapeutic actions. 
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Chapter II 
Materials and Experimental Methods 
 
2.1. Reagents and experimental tools 
Methanol, ethanol, ethyl acetate, and Iron (III) Citrate nHydrate (Ferric Citrate (FeC6H5O7 
·nH2O)) used for the sample preparations and extractions were from Wako Pure Chemical 
Industries, Ltd. (Osaka, Japan), Silica gels Wakogel C200 and YMC-Gel 12 nm S-150µm 
SL12SA5, ODS YMC-Gel ODS-A 12 nm S-150µm AA12SA5 used for the separation of the 
pigments were from Wako Pure Chemical and YMC Co., Ltd (Kyoto, Japan), respectively. 
Bacto tryptone, Bacto yeast extract used for the preparation of LB-SW culture medium and 
Proteose peptone No.3, Soytone used for the preparation of PPES-II culture medium were all 
from Becton, Dickinson and Company (USA). Polypepton and Agar were from Nihon 
Pharmaceutical Co., Ltd. (Tokyo, Japan) and Naqalai Tesque (Kyoto, Japan), respectively. 
Hitachi Centrifuge himac CR21E (Hitachi Koki Co., Ltd) was used to centrifuge bacterial 
culture and the red pigment extract; rotary evaporator was from As One Corporation (Osaka, 
Japan); Eyela Ceramic reciprocal pump VSP-2050 used for mobile phase pumping was from 
Tokyo Rikakikai Co., Ltd (Japan). Hitachi UV visible spectrophotometer model U-3010 
(Tokyo, Japan) was used to determine the concentration of the pigment. The chromatograph 
used in this study was a Nanospace SI-2 HPLC system (Shiseido, Tokyo, Japan) consisting of 
a two-flow channel degasser, an inert pump, an autosampler, a column oven and a UV-Vis 
PDA detector. An EZChrom Elite Nanospace system software for Shiseido was used to 
control the operation of the HPLC system. Separation of the red pigment and its individual 
compounds were performed on an ODS Capcell Pak C-18 MGII (1.5 mm × 150 mm) column 
purchased from Shiseido Co., Ltd. (Tokyo, Japan). MTP-880 Lab microplate reader (Hitachi 
Biotechnologies) was used to measure PTP1B assay activity using 530 nm emission / 490 nm 
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excitation of the fluorescence intensity. PP2A enzyme activity was measured using 
Benchmark microplate reader (Bio-Rad). NMR spectroscopy of P2 (0.85 mg) was performed 
on a Varian Unity INOVA 400 to obtain 1H (400 MHz) and 13C (101MHz) spectra of the 
pigment in CDCl3 using methods such as 1H-NMR, 13C-NMR, DEPT, HMQC, HMBC, 
COSY and TOCSY. High resolution MS analyses was conducted on Electrospray ionization 
Fourier transform mass spectrometer (ESI-FTMS) (Exactive, Thermo Fisher).  
 
2.2. Cultivation of the red pigment-producing 1020R bacterial strain 
PPES-II culture medium used for the cultivation of 1020R strain in a plate contained 2.0 g 
Polypeptone, 1.0 g Proteose peptone No.3, 1.0 g Soytone, 1.0 g Bacto yeast extract, 0.1 g Iron 
(III) Citrate nHydrate and 15 g Agar in 1L volume adjusted to pH 8.0 with 1 or 5M NaOH. 
Lurie-Bertani sea water (LB-SW) culture medium used for the cultivation of the 
bacterium contained 10g of tryptone, 5g of yeast extract in 1 L of seawater adjusted to pH 8.0 
with 5 M NaOH solution. Sea water was filtered through paper filter before using. All culture 
mediums were sterilized at 121ºC for 20 min at maximum 0.4 MPa pressure before usage. 
The procedure for the cultivation of the 1020R bacterial strain to produce the red 
pigment consisted of the following steps: First, a single colony from the agar plate was 
transferred into the test tube containing 5 ml of LB-SW medium and was incubated overnight 
with rotation at 28°C. Then, from this culture, a sample of approximately 1% of total volume 
was transferred to a flask also containing LB-SW medium, and cultivated with intensive 
shaking at 120-130 rpm/min for 1 or 2 days. The change of the clear culture medium to a 
turbid view was indicative of the sufficient bacterial growth. Then, from this medium, again a 
sample of approximately 1% of a total volume was transferred to many flasks, all containing 
LB-SW medium, for the production of the red pigment. The culture medium was incubated in 
the dark at 28°C for 7-8 days to get the maximum amount of the red pigment. After that the 
red pigment was extracted. 
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2.3. Extraction of the red pigment 
Dark red coloured bacterial culture broth was first centrifuged at 8,000 rpm for 15 min at 4°C 
to precipitate bacterial cell mass with the red pigment. The obtained supernatant, which also 
contained a little amount of the red pigment, was subjected to the extraction with ethyl acetate 
while precipitate, which contained the most amount of the pigment, was thoroughly dissolved 
in pure ethanol with aggressive mixing to disrupt bacterial cell wall and centrifuged again at 
10,000 rpm for 10 min at 4°C. The supernatant with the red pigment was taken and the 
precipitate was treated again 2 times with ethanol to remove the red pigment remnants and 
then discarded. The supernatant was collected and then dried using a rotary evaporator. To 
remove remained salt in the red pigment, it was again dissolved in pure ethanol and 
centrifuged at 10,000 rpm for 10 min at 20°C. 
UV visible spectrum of the red pigment was measured on U-3010 Spectrophotometer in 
the range of 200-800 nm, which showed the maximum absorbance at around 533.0 to 537.0 
nm. Concentration of the red pigment was measured according to maximum absorbance 
height using Beer-Lambert Law applicable for the solutions. 
A = ε l c 
Where, A is an absorbance; ε is the molar absorptivity of the solution; l is the length of 
solution the light passes through (cm); c is the concentration of solution in mol/L. 
Considering the molar absorptivity ε of the red pigment is equal to 1.12 × 105 and the 
length of solution is 1 cm, the above formula roughly turns to the following: 
 
 
Where, C is the mass of the red pigment in mg; 323.23 is the molecular weight of 
prodigiosin as the main compound of the pigment; X is the volume of the red pigment 
C=           ×           × 323.23 × 1000 =            = 0.00288 X A (mg) 
A 
1.12 × 105 1000 
X 
1.12 × 105 
323.23 X A 
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solution in ml; A is the maximum absorbance at around 535.0 nm. 
 
2.4. HPLC analysis 
HPLC measurements were performed isocratically at a flow rate of 100 µl/min using the 
mobile phases mostly CH3OH/H2O and CH3CN/H2O for the method development. The ratio 
of CH3OH in the mobile phase was varied from 50 to 70% to find an optimum separation 
condition. Eventually, the ratios consisting of CH3OH/H2O - 55/45 (v/v) and 50/50 (v/v) 
added 0.2% of acetic acid were chosen as optimum mobile phases to analyze the red pigment 
and its individual compounds. HPLC analysis was performed after each extraction, Silica and 
ODS open column separation processes to evaluate the purity of the pigment and its 
individual compounds. 
It should be noted that previously HPLC analysis of the red pigment was performed 
using CH3OH/H2O - 70/30 (v/v) added 0.2% of acetic acid as a mobile phase and revealed to 
contain 5 individual compounds. However, recent analysis performed using CH3OH/H2O - 
55/45 (v/v) and 50/50 (v/v) added 0.2% of acetic acid have revealed that the red pigment 
extracted from 1020R strain may actually contain at least seven compounds than originally 
found, and thus it should also be studied more in detail for what we concentrated here. 
 
2.5. Cytotoxicity assay 
U937, K562 and HL60 leukemia cancer cell lines were cultured in RPMI medium 
supplemented with 10% fetal bovine serum. Approximately, 1 × 106 cells/ml were incubated 
with different concentrations of prodigiosins varying from 0.1 to10 μM in 24 well plates for 
24, 48 and 72 hrs at 37°C humidified with 5% CO2. Cytotoxicity was determined by the MTS 
assay employing the reaction that 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)- 
2-(4-sulfophenyl)-2H-tetrazolium in the presence of phenazine methosulfate (PMS) produces 
a formazan product that has an absorbance maximum at 490-500 nm in phosphate-buffered 
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saline. Thirty μl of MTS buffer was added to each well of 96 well plates containing 30 μl of 
the culture medium and the absorption at 490 nm was measured after incubation. Cell 
medium only and DMSO added to the cell medium instead of prodigiosins were used as 
positive controls. 
 
2.6. Effect of the pigments on protein kinase and protein phosphatase enzymes 
2.6.1. Phosphorylation experiments 
Protein tyrosin kinase (Src kinase) and CaM kinase were assayed according to the 
maufacturer’s instructions, in a final volume of 50 μl of buffer containing 5 μl of the red 
pigment dissolved in DMSO, 50 mM Hepes-NaOH pH7.4, 10 mM MgCl2, 1 mM EGTA, 200 
μM p60c-src substrate for Src kinase or 50 μM autocamtide for CaM kinase, and 200 μM 
[γ-32P]ATP (specific radioactivity, 4.2 KBq/nmol). Additionally, for the assay of CaM kinase, 
5 mM CaCl2 and 30 μg/ml calmodulin were added. 
PKA and PKC catalytic subunits were assayed according to the method of Toomik and 
Ek [198], by modifying and optimizing the experimental procedure. The phosphorylation 
reaction by PKA was performed in 100 μl of buffer containing 5 μl of the red pigment 
dissolved in DMSO, 25 mM Tris-HCl, pH 7.5, 9.4 mM MgCl2, 100 μM kemptide, 0.1 mg/ml 
ovalbumin, 10 units/ml PKA catalytic subunit and 190 μM [γ-32P]ATP (specific radioactivity, 
1.0 KBq/nmol).  
Phosphorylation experiments with PKC were carried out in a final volume of 100 μl of 
buffer containing 5 μl of the red pigment dissolved in DMSO, 20 mM Tris-HCl pH7.5, 10 
mM MgCl2, 20 μM PKC [Ser-25] (19-31) peptide substrate, PKC catalytic subunit and 100 
μM [γ-32P]ATP (specific radioactivity, 2.8 KBq/nmol). Samples containing PKA and/or PKC 
and DMSO, but not the red pigment were used as positive, while enzyme free samples were 
used as negative controls. The experiments were carried out in duplicate or triplicate at 30°C 
for either 10 or 20 min. The reactions were initiated by the addition of 5 μl [γ-32P]ATP 
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solution and stopped by the addition of 10 μl 800 mM H3PO4 solution. Incorporated 
radioactivity was measured for 10 min by Cerenkov counting in a Beckman LS 6500 
scintillation counter (Beckman Instruments, Inc. Fullerton, CA, USA). 
 
2.6.2. PTP1B assay 
The CycLex® PTP1B Fluorometric Assay Kit (Cat. No. CY-1350) was used as an 
experimental tool. The experiments were performed in 96-well plates containing 40 μl of 
reaction buffer, a PTP Fluoro-Phospho-Substrate, recombinant PTP1B enzyme, 20 μl of 
development buffer, 5 μl of development reagent and the red pigment dissolved in DMSO at 
different concentrations as test compounds in a total of 75 μl reaction volume. The reaction 
was stopped by adding 25 μl of stop solution. The fluorescence intensity was measured at 530 
nm emission vs. 490 nm excitation in a microplate reader. Samples containing DMSO but not 
prodigiosins were used as positive, and those containing no enzyme and inhibitor (included in 
the kit) as negative controls. 
 
2.6.3. PP2A assay 
SensoLyte® pNPP colorimetric protein phosphatase assay kit (AnaSpec, Cat. No 71105) was 
used to examine in vitro inhibitory activity of the pigments. Reactions were performed in a 
96-well plate in a total of 100 μL assay volume containing 40 mM Tris-HCl (pH8.4), 34 mM 
MgCl2, 4 mM EDTA, and 4 mM DTT, 5 μL of the red pigment dissolved in DMSO at 
different concentrations ranging from 1-50 μM, and 50 μL of the pNPP solution as a generic 
substrate. The reaction was performed at 30ºC for 1 h and terminated by the addition of 50 μL 
stop solution. pNP formed as a result of dephosphorylation from the initial pNPP by the PP2A 
enzyme was measured at 405.0 nm. Samples containing DMSO but not the red pigment were 
used as positive controls. 
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Chapter III 
Results and Discussion 
 
3.1. Cultivation, isolation and purification of the red pigment 
The procedure of cultivation of the strain 1020R consisted of the following steps: First, a 
single colony from the agar plate (Fig.3.1) was transferred to the test tube containing 5 ml of 
LB-SW medium and was incubated overnight with continuous rotation at 28°C. Then from 
this culture broth a sample of approximately 1% of total volume was transferred to a 200 ml 
flask containing 30 ml of LB-SW medium, and cultivated with intensive shaking for 1 or 2 
days. When the clear culture medium became turbid, indicating sufficient bacterial growth, a 
sample of approximately 1% of total volume was transferred to 500 ml flasks, all containing 
200 ml of LB-SW medium, for the production of the red pigment. The bacterial culture 
mediums were incubated for 7-8 days at 28°C to get the maximum amount of the red pigment. 
After that the red pigment was extracted. Extraction of the red pigment was carried according 
the the scheme showed below (Scheme 3.1). 
 
Fig.3.1. 1020R strain colony on agar plate 
Extraction of prodigiosin compounds was carried out both from the supernatant and 
precipitate after centrifugation of the bacterial culture medium. This process was very 
complicated as the extraction of the prodigiosin compounds from the supernatant was 
extremely difficult and required more time and solvents to be used. To find an optimum 
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medium for the pigment production and also to facilitate the one step procedure of the 
extraction, pH dependent cultivation of the bacterium was carried out. For this reason, pH 6.0, 
6.5, 7.0, 7.5 and 8.0 were chosen to cultivate the strain. The experiments showed that the most 
of the pigment was precipitated after the first centrifugation of the bacterial culture broth in all 
pH mediums except pH 8.0, while at pH 8 the pigment mainly remained in the supernatant 
(Fig.3.2). 
 
Fig.3.2. Supernatant after the first centrifugation of bacterial culture broth. Left flask pH 
6.0, 6.5, 7.0, 7.5, right flask pH 8.0. 
Fig.3.2 clearly shows that the centrifuged culture mediums have different red colour 
intensities, indicating that the amount of the red pigment may sometimes be higher in the 
supernatant rather than in the precipitate at pH 8, indicating an impact of the pH of the 
medium on the red pigment production. Furthermore, the highest amount of the pigment was 
isolated from pH 7 medium, but not pH 8. It should be noted that until now for the production 
of the prodigiosins, strain 1020R was cultivated at around pH 8 which is close to the pH of 
seawater. However, this pH medium seems unsuitable for the cultivation of the bacterium. In 
case of pH 6 to 7.5, there was no need to extract the pigment from the supernatant, while at 
pH 8.0 the highest amount of the pigment was extracted namely from the supernatant, which 
made the extraction procedure much more complicated. 
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Fig.3.3. pH dependent cultivation of the strain 1020R and the amounts of the pigment 
extracted. Red pigment extracted from the precipitate    and from supernatant   . 
It is likely that the red pigments are associated with proteins in original form as soluble 
protein-red pigment complexs at pH 8, and the disruption of the complexes occurs during the 
extraction procedure, making the red pigments insoluble in water [73]. 
A similar phenomenon was previously demonstrated by Velmurugan et al. [199], who 
examined the effect of pigment formation in fungi by five pigment-producing filamentous 
fungi in synthetic medium. However, the effect of pigment formation in bacteria was not 
investigated in their study. This observation, thus suggests that the pigment production may 
be similar in these two species. 
Extraction procedure carried out from both the supernatant and precipitate is shown in 
the scheme below (Scheme 3.1). The amounts of the red pigment taken from the supernatant 
ranged from 1.2 to 6.36 mg/Land from the precipitate 1.86 to 8.37 mg/L. The overall amount 
of the red pigment extracted from 1020R bacterial strain made up approximately 4.27 to 14.58 
mg/L. The extracted red pigments from both the supernatant and precipitate were collected 
and, after HPLC analyses, were subjected to the column separations. 
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Scheme 3.1. Extraction of the red pigment from bacterial culture broth. 
 
Previously, it was suggested that shaking of bacterial culture medium negatively affects 
to the pigment production by 1020R strain. However, it was observed during the experiments 
that intensive shaking of bacterial culture medium at 180 rpm or more led to the intensive red 
pigment production by the bacterium. This was quite in accord with the investigation of Wei 
et al. [196] who found undecylprodigiosin production in S. marcescens may be enhanced by 
increasing the agitation rate. However, in this study the influence of agitation rate to the 
pigment production by 1020R strain was not investigated in detail. 
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3.2. Column separation 
3.2.1. Silica gel open column separation 
After many steps of extraction shown in the scheme above, the extracted pigments were 
collected and subjected to column separations using silica gel first and then ODS as stationary 
phases. Approximately 9 mg of the crude red pigment in ethanol was dried by rotary 
evaporator, redissolved in 5 ml of CHCl3 and loaded onto the column (2.5 X 52 cm) tamped 
down with silica gel particles (Wakogel C200 or YMC-Gel Silica 12 nm S-150µm), 
equilibrated in chloroform. Separation was performed in a self-flowing manner at a flow rate 
of 5-10 ml/min, eluting first with pure chloroform, following by chloroform/methanol in a 
different ratios (Fig.3.4). Although, there were many peaks obtained from the gradient 
separation of the pigments, only the first fraction eluted by the pure chloroform was subjected 
to further separation by ODS column chromatography.  
 
Fig.3.4. Silica gel open-column separation of the crude red pigment isolated from 1020R 
strain. Elution order: 0-310 ml with 100% CHCl3; 320-400 ml with CH3OH/CHCl3 – 6/94 
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(v/v); 410-600 ml with CH3OH/CHCl3 – 10/90 (v/v); from 610 ml with CH3OH/CHCl3 – 
20/80 (v/v). 
However, HPLC analysis of the pure chloroform and chloroform/methanol fractions 
showed that they contain the same quantity of compounds. The sample eluted in pure 
chloroform had a bright red colour, subsequently changing into brownish-red in 
chloroform/methanol fractions, and violet in pure methanol fraction. As the aim of this study 
was to isolate individual compounds of the pigment, it was further decided to perform only 
ODS open column separation of the pigment, taking into account that the considerable 
amounts of the compounds might be lost by discarding chloroform/methanol fractions after 
silica gel open column separation. 
 
3.2.2. ODS open column separation 
ODS separations of the pigment were carried out using columns 2.5 × 52 cm and 1.0 × 30 cm 
tamped down with ODS gel (YMC Gel ODS-A 12 nm S-150 µm). 
The red pigment loaded onto the column was eluted using the mobile phase consisting of 
CH3OH/water – 60/40, 65/35, 70/30 and 80/20 (v/v) acidified by adding 0.2% of acetic acid. 
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Fig.3.5. ODS open column separation profile of the red pigment. 
As a result, main five fractions were obtained, being eluted in CH3OH/H2O – 60/40 (P-1, 
P-2, P-3 and P-4), 65/35 (P-5), 70/30 (P-6 and P-7) and in 80/20 (fifth peak) added 0.2% 
acetic acid. 
The colour of the samples changed from bright red to brownish red and the last fraction 
eluted in pure methanol had a violet colour (Fig.3.6). 
  
Fig.3.6. Red pigment fractions obtained from ODS open column chromatography 
separation and the comparison of the first and the last eluted fractions of the pigment. 
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3.3. HPLC analysis 
Mobile phases consisting of CH3OH/H2O and CNCH3/H2O at different ratios acidified by 
addition of 0.2% of acetic acid were used to find the optimum separation condition in 
isocratic separation mode. Mobile phase consisting of CH3OH/H2O – 50/50 (v/v) + 0.2% 
acetic acid was found to be suitable for the pigment separation except for longer analysis time. 
CH3OH/H2O – 55/45 (v/v) + 0.2% acetic acid was also suitable with shorter analysis time, 
although the first eluted P-1 and P-2 compounds were not fully separated. Eventually, 
CH3OH/H2O – 50/50 (v/v) + 0.2% acetic acid was decided to use for the detailed analyses, 
while mobile phase consisting of 55% CH3OH for quicker analyses of the pigments. Other 
conditions were set as follows: Column used was ODS Capcell Pak C-18 MGII (1.5 mm × 
150 mm); column temperature - 40°C; flow rate - 100 µl/min. 
HPLC analysis of the ODS open column separation fractions showed that the fraction 1 
contained the first eluted P-1 & P-2 compounds (Fig.3.7), which accounted for 3.58-13.55% 
of the total amount of the pigment. 
 
Fig.3.7. HPLC analysis of the ODS separated fraction 1 eluted in CH3OH/H2O – 60/40 + 
0.2% acetic acid. HPLC system: Shiseido Nanospace SI-2. Chromatographic conditions: 
Column: ODS Capcell Pak C-18 MGII (1.5 mm × 150 mm); mobile phase: MeOH/H2O – 
P-1 
P-2 
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50/50 (v/v) + 0.2% acetic acid; column temperature: 40ºC; flow rate: 100 µl/min. 
Fraction 2 contained P-3 and the most abundant compound of the red pigment - P-4 
(Fig.3.8), making up 33.5% of the total amount of the pigment. 
 
Fig.3.8. HPLC analysis of the ODS separated fraction 2 eluted in CH3OH/H2O – 60/40 + 
0.2% acetic acid. HPLC system and the separation conditions are the same as in Fig.3.7. 
Fraction 3 contained the next most abundant P-5 compound, the amount of which varied 
between 3.33 to 17.7% of the total amount of the pigment (Fig.3.9). 
 
Fig.3.9. HPLC analysis of the ODS separated fraction 3 eluted in CH3OH/H2O – 65/35 
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+0.2% acetic acid. 
Fraction 4 contained the last eluted compounds of the red pigment – P-6 and P-7 
(Fig.3.10), varying between 0.21-1.55%. 
 
Fig.3.10. HPLC analysis of the ODS separated fraction 4 eluted in CH3OH/H2O – 70/30 
+0.2% acetic acid. HPLC mobile phase CH3OH/H2O – 55/45 (v/v) + 0.2% acetic acid. Other 
conditions are the same as in Fig.3.7. 
The last fraction 5 eluted in CH3OH/H2O – 70/30 +0.2% acetic acid did not contain any 
pigmented compound. 
As the main task of this investigation was to separate the first eluting P-1 & P-2 
compounds individually, an attempt was made to re-separate fraction 1 using ODS open 
column with methanol/water as a mobile phase, hoping to get the individual compounds. As a 
result, three fractions were obtained (Fig.3.11). 
P-6
P-7
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Fig.3.11. ODS re-separation of the fraction 1 (the fraction shown in Fig.3.7). 
Although the elution profile showed excellent separation of the two compounds, further 
HPLC analysis of these fractions revealed that the (F-1-1) – fraction, which was eluted in the 
mobile phase methanol/water – 45/55 (v/v) + 0.2% acetic acid contained mostly P-1 
compound and a small amount of P-2 compound (Fig.3.12). 
 
Fig.3.12. HPLC analysis of the F-1-1 and F-1-2 fractions eluted in the mobile phase 
CH3OH/H2O – 45/55 and 55/45 (v/v) + 0.2% acetic acid. HPLC system and the separation 
conditions are the same as in Fig.3.7. 
HPLC analysis of the F-1-2 fraction showed that it mainly consisted of P-2 and a trace 
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amount of P-1 (Fig.3.12). Although, separated fractions still contained both the major 
compound and a small amount of the other red pigment compound as expected, it was 
concluded that their separation can be achieved by two ODS cycles. 
The approximate contents of the two compounds were calculated by measuring their UV 
absorbance between 200-800 nm. The observed max absorbance at 535.0 nm, confirmed that 
they belong to the prodigiosin-like compounds which accounted for about 1.27% and 0.5%, 
respectively, of the total amount of the crude red pigment loaded onto ODS column. 
As the amounts of pigments were extremely low, the two cycle separation procedure was 
carried out repeatedly until obtaining the least amounts of compounds for the structural 
analyses. However, during the accumulation and preservation, it was noticed that the 
concentrations of the pigments changed due to their degradation. Especially, P-1 compound 
was found to be unstable as it decomposed faster into other unknown compounds, making 
impossible to analyze its chemical structure. Newly appeared compounds as a result of 
decomposition showed the max absorption in the vicinity of 535 nm as prodigiosins give max 
absorbance, suggesting some of them may belong to prodigiosin family or containing the 
same chromophore groups as the red pigment compounds. However, the peaks also appeared 
at the ranges between 200-220 and around 300 nm, suggesting that some of newly appeared 
compounds may not belong to prodigiosin family. The color of the pigment gradually 
changed from red to yellow or became even colorless, with intermediate brownish-red, brown 
and brownish-yellow. Furthermore, when the temperature around 39°C was applied to dry the 
pigments, the decomposition process was accelerated, which was also visible from the color 
change of the pigments from red to yellow. This was confirmed by HPLC analysis of the 
samples, which showed additional peak(s) appeared in the chromatogram (Fig.3.13) at around 
300 nm. 
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Fig.3.13. HPLC chromatograms of the red pigment samples showing the decomposition 
occurred with the pigment individual compounds. A – 535.0 nm, B – 300.0 nm. 
Later, it was observed that not only P-1, but the amounts of other pigments were also 
tending to decrease, i.e. the concentrations of the separated individual compounds were not 
stable, suggesting the decomposition process occurring with other compounds of the red 
pigment too. These were confirmed on HPLC analyses of the compounds. The degradation of 
the prodigiosin compounds occurred despite keeping them in dark and cold place, as these 
compounds are very sensitive to light [200]. 
 
Fig.3.14. HPLC analysis of the fraction containing P-1 and P-2 before (A) and after 
degradation (B). HPLC System: Shiseido Nanospace SI-2. Chromatographic conditions: 
Column: ODS Capcell Pak C-18 MGII (1.5 mm × 150 mm); mobile phase: CH3OH/H2O – 
50/50 (v/v) + 0.2% acetic acid; column temperature: 40ºC; flow rate: 100 µl/min. 
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pigment is extracted from the bacterial culture broth. As time passes, and especially, after 
ODS open column separation of the crude red pigment, the amount of P-1 decreases. This 
became considerable after keeping it around one month in methanol. Newly appeared peaks 
and the decreased amount of P-1 were clearly seen when the fraction mostly containing P-1 
and lesser amount of P-2 was analyzed on HPLC after keeping it for nearly two months in 
methanol (Fig.3.14). Due to instability, resulting in decomposition, the chemical structure of 
P-1 was not analyzed. Approximately 0.85 mg of P-2 was collected for the structural analysis 
of the compound (Fig.3.15). 
 
Fig.3.15. HPLC analysis of P-2 in the mobile phase of CH3OH/H2O – 60/40 (v/v) + 
0.2% acetic acid at 535.0 nm. HPLC system and the other separation conditions are the same 
as in Fig.3.14. 
 
3.4. Structural analysis of P-2 
The chemical structure of P-2 was analyzed using the physicochemical methods of 
investigation such as high resolution electrospray ionization Fourier transform mass 
spectrometry (ESI-FTMS) and NMR spectroscopy, including 1H-NMR, 13C-NMR, DEPT, 
HMQC, HMBC, NOESY, COSY and TOCSY (Appendix 2) as well as by comparison with 
P-2
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previously obtained data from other pigments investigations. ESI-FTMS analyses showed the 
probable existence of 2-methyl-3-butylprodiginine, since the highest positive-ion signal at 
m/z 310 [M+H]+ corresponds to the molecular weight of this compound, and also a signal at 
m/z 252 coincidents to the mass of its core structure. In addition, the fragment ion m/z 295 
was assumed to be produced by the removal of the CH3 moiety from the methoxyl residue of 
the P-2. The comparison of this spectrum with previously obtained mass spectrum for the 
2-methyl-3-pentylprodiginine, i.e. prodigiosin showed the chemical structure smaller by 14 
Da (CH2) than prodigiosin, suggesting the structure with shorter alkyl group. Theoretical and 
observed spectral data of the compound has almost the same mass-to-charge ratios, showing 
good compliance to the suggested chemical structure. 
Fig.3.16. ESI-FTMS analysis of P-2 and its comparison with MS data of P-4, previously 
determined to be 2-methyl-3-pentylprodiginine or prodigiosin. 
The suggested chemical structure was confirmed by NMR spectroscopy analyses of the 
compound. The 1H-NMR and 13C-NMR data for P-2 were coincident with those of 
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prodigiosin (2-methyl-3-pentylprodiginine) previously reported by our research group [201]. 
This was proved by additional DEPT, HMQC, HMBC, NOESY, COSY and TOCSY, 
experiments. 
In the 1H-NMR spectrum of P-2, NH group, H signals of six pyrrole alkaloids, one 
methoxy group and five groups of alkyl chain protons in the high magnetic field were 
observed, suggesting the existence of pyrrolypyrromethene structure. 13C-NMR analyses also 
showed the existence of methoxy group which was differed from the signals of methyl groups 
at the C-ring and in the alkyl chain. The final conclusion came from the TOCSY analysis 
which confirmed the existence of methoxy and methyl groups and also alkyl chain length to 
be equal to butyl group at c-3 position by overlapping signals in 2D measurements. 
 
Fig.3.17. Signal correlations observed in TOCSY spectrum of P-2. 
It should be noted that although the existence of 2-methyl-3-butylprodiginine (previously 
it was depicted as pigment 1, but now P-2) was previously suggested on the basis of MS data 
[47, 79, 201, 202] this compound had not been isolated to investigate by NMR. This is the 
first detailed structural characterization of P-2 by NMR spectroscopy. NMR data of P-2 gave 
the following signals: 
1H-NMR (CDCl3, 400MHz) δ0.93 (3H, t, H-c4’’), 1.35 (2H, m, H-c3’’), 1.52 (2H, m, 
H-c2’’), 2.41 (2H, t, H-c1’’), 2.54 (3H, s, CH3), 4.01 (3H, s, H-OCH3), 6.09 (1H, d, H-b4), 
6.36 (1H, m, H-a4), 6.69 (1H, d, H-c4), 6.92 (1H, m, H-a3), 6.96 (1H, d, H-1’), 7.20 (1H, m, 
H-a5), 12.72 (brs, H-NH-a), 12.56 (brs, H-NH-b); 
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13C-NMR (CDCl3, 101MHz) δ12.5 (c-CH3), 14.1 (c4’’), 25.1 (c1’’), 32.2 (c2’’), 22.3 
(c3’’), 58.7 (OCH3), 92.8 (b4), 111.7 (a4), 116.0 (1’), 117.0 (a3), 121.0 (b2), 123.3 (a2), 
125.2(c5), 127.0(a5), 128.4(c4), 128.5 (c3), 147.1 (c2), 147.7 (b5), 165.8 (b3). 
 
3.5. Investigations on the stability of the red pigment compounds 
Although, it is not clear to what kinds of compounds may convert or decompose P-1 and other 
prodigiosin compounds and what causes their decomposition, it seemed that the 
environmental conditions, i.e. temperature and solvent might play a crucial role in this process. 
Therefore, the impact of environmental conditions, i.e. temperature and solvents on the 
stability of the pigments were investigated. For this reason, a crude extract of the red pigment 
and the red pigment purified through silica column consisting of the mixture of all prodigiosin 
compounds were dissolved in DMSO, methanol, acetone, ethyl acetate, 2-propanol and also 
dried samples were kept for 4 months at 4°C and at room temperature in a dark place. 
 
All the samples were analyzed by HPLC once in every month. As a result of this 
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investigation, the impacts of the solvents and environmental conditions were found to be 
essential. Among the solvents used to dissolve the prodigiosin compounds, DMSO followed 
by methanol were found to be the most aggressive to destroy the pigments. These two 
solvents were the most often used solvents to dissolve the red pigment samples. So, it seems 
that, by dissolving the red pigments, samples always undergo destruction. 
 
The degradation process was accelerated at room temperature samples when compared to 
the samples kept at cool temperature. It is interesting to note that even dry samples were 
tending to degradation, indicating that the dry condition is not a guarantee to keep the red 
pigment samples. However, the environmental conditions, i.e. solvents and temperature, do 
not seem the main causes of the degradation of compounds. Especially, the crude red pigment 
samples which were not purified through silica gel were degraded faster even if they were 
kept at 4°C. The red pigment samples purified through silica gel prior to stability experiments 
have become more stable, though the decrease in the amounts of individual prodigiosin 
compounds was still observed. Probably, this could be due to the presence of high polar small 
molecule compounds, which could be mostly retained in silica gel during the purification of 
the red pigment. These compounds, which do not contain chromophore groups to be detected 
on HPLC analysis, might play a role of catalytic agents to initiate the degradation of 
prodigiosin compounds. However, this suggestion needs additional investigations to be 
confirmed. 
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3.6. Cytotoxicity of prodigiosins against human U937, K562 and HL60 leukemia cell 
lines 
Cell cytotoxicity experiments of prodigiosins were carried out on human U937, K562 and 
HL60 leukemia cell lines by assessing their effect on the MTS reduction assay. As can be 
seen from Fig. 3.18, the red pigment resulted in significant decrease in the percentage of the 
viable cells. IC50 value of prodigiosins against U937 cells was about 0.7 μM (Fig. 3.18 A) 
while it was around 1.5 μM in HL60 (Fig. 3.18 B) and around 2.5 μM in K562 (Fig. 3.18 C) 
cells. 
 
 
Fig.3.18. Effect of the mixture of the red pigment at increasing concentrations on U937 
(A); HL60 (B); K562 (C) cell lines and the effect of individual compounds (2 μM) on U937 
cell lines (D). 
Among the individual prodigiosin compounds, P-4, i.e. 2-methyl-3-pentylprodinine or 
prodigiosin showed the highest apoptotic effect (Fig. 3.18 D) against all the tested cancer cells, 
followed by P-5 (2-methyl-3-hexylprodinine), the mixture of P-6 and 7, and P-7. The lowest 
effect of P-2 suggests to its lowest hydrophobicity compared to other analogs that may hinder 
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it to penetrate through the lipid bilayer of the cells to initiate the apoptotic processes. 
 
3.7. Effects of prodigiosin compounds and violacein on the activities of protein 
phosphatases and protein kinases 
It is well-known that both the prodigiosin compounds and violacein have a wide variety of 
pharmacological activities, including antibiotic, immunosuppressive (only prodigiosins) and 
above all cytotoxic effect against malignant tumor cells. Some molecular mechanisms of 
cytotoxicity of both types of compounds identified until now, which can be the case to cause 
the programmed cell death, are mentioned in the Introduction part. However, the full 
mechanisms of action remain elusive, requiring more deeper and precise investigations. 
To contribute to the better understanding of the molecular mechanisms of cytotoxicity, in 
our research we studied the effect of the red pigments and violacein on protein kinases and 
protein phosphatases which are known to play a significant role in the intracellular signal 
transduction pathway. It should be noted that Fürstner and coworkers [100] were the first who 
showed that roseophiline and some synthetic prodigiosin analogues inhibit protein tyrosine 
phosphatase activity. They suggested that this inhibitory effect of the compounds may be 
employed to cure the malignant diseases. However, the phosphatases inhibition by naturally 
derived prodigiosin compounds has not been investigated. 
On the other hand, Bromberg et al. reported violacein’s effect on the total protein 
phosphatases activity extracted from human lymphocytes [189]. However, violacein effect on 
protein kinases was not investigated so far. Taking into account the importance of the role of 
signaling pathway molecules in cells, we studied the effect of prodigiosin and violacein 
compounds on some representative members of protein kinases and protein phosphatases to 
investigate whether these important enzymes are involved in the pigments cytotoxic effect. 
Selected members of kinase and phosphatase family enzymes were tested in vitro to assess the 
inhibitory effects of prodigiosin and violacein compounds. Structure-activity relationship 
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(SAR) of prodigiosin compounds was also studied. 
 
3.7.1. Effect of prodigiosin compounds and violacein on phosphorylating activity of 
protein kinases 
The effects of prodigiosin compounds and violacein were investigated on the catalytic 
subunits of protein kinase A (PKA) and C (PKC), including PKC subfamily isozymes as well 
as Src-protein tyrosine kinase (Src-PTK) and calmodulin-dependent protein kinase (CaM 
kinase). Fig. 3.19 shows the effect of prodigiosins on CaM kinases activity. The enzyme 
activity remained almost intact (Fig.3.19), showing phosphorylation activities similar to 
positive DMSO control. The prodigiosins also showed no remarkable effect (data not shown) 
against PTK enzyme activity, too. Consequently, both PKA and PKC activities were not 
either induced or inhibited by the red pigment and its individual compounds (data not shown). 
From these results, we conclude that protein kinases may not be direct targets of prodigiosins. 
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Fig.3.19. CaM kinase inhibition assay by prodigiosin compounds 
On the other hand, violacein showed inhibitory effect on the catalytic activities of both 
PKA and PKC. The activities of the enzymes gradually decreased by increasing the 
concentration of violacein, indicating that the inhibition was dependent on the concentration 
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of violacein. The IC50 values for PKA and PKC were equal to 6 and 2 μM, respectively 
(Fig.3.20). In the experiments, violacein inhibited all the conventional types of PKC isozymes, 
with different level of inhibition. It has also an inhibitory effect on some but not all novel 
types of PKCs, while causing slight inhibition of ζ isozyme which belongs to atypical type of 
PKC (Fig.3.20). However, violacein failed to inhibit Src-PTK and CaM kinase activities. 
 
Fig.3.20. Violacein effect on PKA and PKC catalytic subunits as well as PKC isozymes. 
These results suggest that the chemical and conformational structures of the enzymes 
may play an important role in binding with violacein and prodigiosins to cause the inhibition 
of the enzyme activities. 
 
3.7.2. Effect of prodigiosin compounds and violacein on dephosphorylating activity of 
protein phosphatases 
3.7.2.1. Effect of prodigiosin compounds and violacein on PTP1B enzyme activity 
Experiments were carried out according to the assay kit instructions, with some modifications. 
In the assay, while violacein showed little effect on the enzyme activity, the mixture of 
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individual compounds of the red pigment gradually decreased and completely inhibited the 
enzyme activity at 10 μM, showing almost the same result as inhibitor and/or no enzyme 
controls (Fig.3.21 A). 
 
 
 
 
 
 
 
Fig.3.21. PTP1B inhibition assay by the red pigment (A) and its individual compounds 
(B) tested at 10 μM. Data represent a typical result from two independent experiments and the 
mean values of enzyme activity assayed in duplicate. 
Further investigations of the individual prodigiosin analogs on structure-activity 
relationships (SAR) were conducted in detail, to assess the most influential compound against 
the enzyme activity. For this reason, the red pigment was freshly isolated from the bacterium 
and its individual compounds were separated through the silica and then ODS column 
chromatography. While P-1 was not used for the experiments due to its instability, P-6 was 
used in the mixture with P-7 as the residual amount of the latter was found in its fraction 
(about 5~10%) 
For the experiments, each compound was prepared at 10 μM concentrations. The 
obtained result shown in Fig.3.21 B demonstrated that the pigment 2 has the highest effect on 
the enzyme activity. The activities of other compounds gradually decreased in the elution 
order from HPLC column, i.e. increased alkyl chain length in the structure decreased the 
inhibitory effect of the compounds. 
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3.7.2.2. Effect of prodigiosin compounds and violacein on PP2A enzyme activity 
In the beginning, optimum experimental conditions were established prior to carry out the 
main experiments. Particularly, the content of the reaction mixture, the amount of enzyme and 
the pigments to be used for the experiments as well as the optimum incubation time were 
found experimentally. 
As in the case of PTP1B assay, in order to test which individual prodigiosin compound 
has the most influence on the enzyme activity, they were examined at the concentration of 10 
μM. As a result, the individual compounds of the red pigment caused strong inhibition of the 
enzyme activity (Fig.3.22. A). 
 
Fig.3.22. Effect of individual compounds of the red pigment (A), P-2 and violacein (B) 
on PP2A enzyme activity. All individual compounds were 10 μM. Data represent a typical 
result from two independent experiments and the mean values of enzyme activity assayed in 
duplicate. 
Again, the P-2 along with the mixture of P-6 and P-7 showed the highest inhibitory 
effect towards the enzyme activity. In contrast to the inhibition of PTP1B, the mixture fraction 
of P-6 and P-7 showed strong inhibition against PP2A enzyme. It is not known whether the 
inhibition is a synergistic effect of both P-6 and P-7. If this is the case, it is suggested that 
PP2A may have at least two binding sites for prodigiosin compounds. Violacein also showed 
inhibitory effect on the enzyme activity, but its inhibitory effect was lower than those of P-2, 
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P-4 and P-6(7) mixtures, and showed a similar extent of inhibition at 10 μM as P-5 and P-7. 
The IC50 value of P-2 was approximately 2 μM, and violacein showed the IC50 value of 
around 15 μM (Fig. 3.22. B). 
 
 
 
 
 
 
 
 
Fig.3.23. Effect of P-4 (prodigiosin) on PP2A enzyme activity. 
The IC50 value of P-4 or prodigiosin was also approximately 2 μM, confirming its high 
inhibitory effect against PP2A enzyme activity. 
 
3.7.3. Combinatorial effect of P-2 and violacein 
As shown in Fig.3.22B, P-2 was a strong inhibitor of PP2A, and violacein moderately 
inhibited the enzyme activity. However, it was found that a certain combination of P-2 and 
violacein elevated the PP2A activity. 
To investigate whether prodigiosin compounds induce PP2A enzyme activity in the 
presence of violacein more effectively, the mixtures of the two pigments, i.e. P-2 and 
violacein were tested against the enzyme activity. For this experiment, violacein concentration 
was set as constant being 10 μM, while gradually increasing the concentration of P-2. 
Although, at higher concentrations of P-2 the enzyme activity was decreased in the presence 
of violacein, at lower concentration it was increased (Fig.3.24). These results suggest that the 
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binding sites of the enzyme might be different for P-2 and violacein. 
 
 
Fig.3.24. Combinatorial effect of violacein (10 μM) and P-2 (1-20 μM) on PP2A enzyme 
activity. 
 
3.7.4. Kinetic analyses of PP2A enzyme by violacein 
The kinetic parameters of the enzyme inhibition by violacein (Fig.3.25 A) showed that Km 
value for the pNPP substrate was roughly to be equal to 22 μl, and the Lineweaver-Burk plot 
of kinetic parameters (Fig.3.25 B) showed that it inhibits the enzyme by non-competitive 
nature of inhibition. 
 
Fig.3.25. Kinetic analysis of PP2A enzyme inhibition by violacein: (A) – determination 
of Km value, and (B) - Lineweaver-Burk plot 
The apoptotic cell death by prodigiosins, which are now under intensive investigations, 
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are known to result from both the extrinsic and intrinsic pathways. Many apoptosis causing 
factors of prodigiosins which have been investigated so far, revealed that mainly the intrinsic 
pathway through mitochondria is involved in the prodigiosin-induced apoptosis [94]. This 
could be explained by the hydrophobic nature of these compounds which enables to penetrate 
through lipophilic membrane bilayer. However, the extrinsic pathway through the death 
receptor signaling is also important, as it was reported not to involve p53 signaling [203]. In 
fact, prodigiosins are known to cause apoptosis through both activation [204] and 
independently [204-206] of p53 tumor suppressor protein and our results are additional 
confirmation of those previously reported investigations. The red pigment showed cytotoxic 
effect on HL60, U937 and K562 leukemia cell lines, with slightly different IC50 values. 
Despite different morphology of the cells, where HL60 and K562 lack p53 protein, 
prodigiosins could still induce apoptosis in both types of cells. This protein is known to be 
involved in a number of cellular processes including gene transcription, DNA repair, cell 
cycling, genomic stability, senescence and apoptosis [207]. It is also known that the lack of 
p53 protein makes cancer cells insensitive to anti-cancer drugs, limiting their clinical efficacy 
as chemotherapeutic agents [208]. Different kinds of cellular signals resulting from DNA 
damage, a defective cell cycle, hypoxia, loss of cell survival factors and other types of cell 
stresses are known to activate this protein which in turn either mediates cell cycle arrest by 
further causing survival or initiates apoptosis through the activation of pro-apoptotic proteins 
[94], thus accelerating the death of injured cells. This process depends on how much the cell 
compartments are damaged. 
However, our results clearly show that prodigiosins induce apoptosis in both types of 
cancer cell lines no matter of existence p53 protein. On this assumption, it is suggested that 
the apoptosis process in these cells is caused through the activation of multiple pathways 
including p53 protein and without its involvement. This confirms our previous study where 
the red pigment caused both DNA fragmentation and caspase 3 activation in U937 cells, 
78 
  
which are considered as stimuli for the activation of p53 [209]. In the case of K562 and HL60 
cells which lack p53, the previous study suggests the possibility of existence of other 
pathways causing apoptosis upon the red pigment effect on these cells. This might be the 
reason for lower effect of prodigiosins onto these cells where the IC50 values were higher than 
in U937 cells. In these cell lines, the extrinsic pathway of apoptosis which may be triggered 
independently from p53 protein [203] can play an essential role. However, considering cell 
permeability of prodigiosins and accumulation in mitochondria [94], it is suggested that the 
intrinsic pathway could still be critical. Therefore, it is essential to investigate the other 
pathways most likely involved in the apoptosis process caused by prodigiosins. Taking this 
into consideration and analyzing previously reported data in literature, we investigate their 
effect on the signal transduction pathway molecules as possible targets of apoptosis. 
The red pigment from strain 1020R was proven to contain seven individual prodigiosin 
family compounds. SAR studies showed that the P-4, i.e. 2-methyl-3-pentylprodiginine or 
prodigiosin has the highest apoptotic effect on the cells, followed by P-5, P-6 and 7, and P-7 
(Fig. 3.18 (D)). The P-2 or 2-methyl-3-butylprodiginine, which has the shortest alkyl group, 
had the lowest effect when compared to its analogs. This could be explained by its lower 
hydrophobicity than that of other analogs. Such low hydrophobicity may hinder it to penetrate 
through the membrane lipid bilayer. On the contrary, P-2 has the strongest inhibitory effect on 
protein phosphatases (Fig. 3.21 B and Fig. 3.22 A). On the other hand, DMSO which is 
mainly used as a drug carrier to increase the effectiveness of chemotherapeutic drugs also 
enhanced the proliferation of leukemia cells. Fig.3.18 B, C and D shows elevated cell viability 
in DMSO at lower concentrations of the red pigment. With increasing the red pigment 
concentration, cell viability decreased gradually, and especially, abruptly after 0.5 μM. This 
observation indicates that the results for the low concentration pigment may not be true due to 
proliferative effect of DMSO that overcame pigments activity. 
To investigate the intrinsic pathway of apoptosis induced by the red pigment, we targeted 
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on kinase and phosphatase family enzymes along with other molecules of the signal 
transduction pathway. Although, inhibition of selective members of protein phosphatases by 
prodigiosin-like compounds has been previously studied [100], the action of prodigiosin and 
its close related analogs on this class of enzymes was not reported. Furthermore, many of the 
previously investigated compounds were mainly synthesized and naturally derived 
compounds were not studied [100]. Additionally, there was no direct evidence of the 
involvement of the protein kinases except indirect inhibition of PKC by prodigiosin [99].  
The obtained results clearly show inhibition of the enzyme activity of tested 
phosphatases, but not kinases. Unlike the phosphatases, kinases do not seem to be direct 
targets for prodigiosins, as all kinases tested in this study were not inhibited or inhibited 
insignificantly, indicating selective action of prodigiosins towards phosphatases. The 
apoptosis-inducing effect on cancer cells (Fig. 3.18) and the inhibitory action against PTP1B 
activity (Fig.3.21) of individual compounds of the red pigment in the order of P-2 to P-7 
suggests that the chemical structures of the compounds play an essential role in their 
biological action. Being similar in chemical structures, they differ only by the length of alkyl 
chain at C-3 position (Fig.3.26) (Chemical structures of P-1, P-3 and P-7 are currently 
remaining unknown). 
 
Fig.3.26. Chemical structures of the red pigment individual compounds: n= 3 - 
2-methyl-3-butyl-prodiginine (P-2); n= 4 - 2-methyl-3-pentylprodiginine (prodigiosin) (P-4); 
n=5 - 2-methyl-3-hexyl-prodiginine (P-5); n=6 - 2-methyl-3-heptylprodiginine (P-6). 
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Although, the exact mechanism of inhibition of enzymes is unknown, it is suggested that 
a structure with shorter alkyl chain more easily penetrates into the active site loop of the 
enzyme molecule. Consequently, the insertion strength increases as the side chain length of 
the compounds at C-3 position extends in the order of P-2 to P-6 (Fig.3.26). Zhang and Zhang 
[210], reviewing the advances on discovery of specific PTP1B inhibitors, pointed out that 
increasing hydrophobicity can be an effective strategy to improve PTP1B inhibitor 
bioavailability due to enhanced permeability through the cell membrane. On the other hand, 
Combs suggested that extremely hydrophobic small molecule inhibitors are not desirable 
agents due to nonspecific inhibition of the enzyme activity [211]. Considering medium 
hydrophobicity and membrane permeability of prodigiosins [94], it seems that these 
compounds could be specific and competitive inhibitors of PTP1B. As the drug discovery 
targeting PTP1B is now considered as a challenging task due to highly conserved and 
positively charged active-site pocket of the enzyme [210], it seems a good sign to be a potent 
drug candidate against type 2 diabetes and cancer [212] that the red pigment and its individual 
compounds have selective affinity towards enzyme with IC50 value of less than 1 μM. 
Another enzyme we investigated was PP2A which belongs to serine/threonine 
dephosphorylating group of phosphatase family. To determine which compound of the red 
pigment has the highest influence on the enzyme activity, newly obtained individual 
compounds of the red pigment were tested at the concentrations of 10 μM, which was resulted 
in strong inhibition of the enzyme activity (Fig.3.22 A). As in the case of PTP1B assay 
(Fig.3.21 B), P-2 along with the mixture of P-6 and P-7 showed the highest inhibitory effect 
towards the enzyme activity. The IC50 value of P-2 was further found to be around 2 μM 
(Fig.3.22 B). This value would be even lower if the only pure enzyme was used. The fact is 
that bovine serum albumin (BSA), added to the enzyme solution at the concentration of 1 
mg/mL to keep its stability, may be the reason for higher IC50 value of the pigment than 
expected. The pigment molecules could probably bind to BSA, thus resulting in lower effect. 
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However, this value is reasonable, considering the existence of dozens of proteins in cellular 
cytoplasm if this experiment would be done in in vivo conditions. 
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CHAPTER IV 
Conclusions 
 
Although, 1020R strain and the red pigment produced by this bacterium were carefully 
studied previously, recent findings have revealed that it must yet to be studied in detail. Many 
interesting phenomena were observed during this study. Interesting was to observe the varying 
amounts of pigments ratio in culture medium, as well as the intensive pigment formation at a 
high rate of shaking of the culture medium which was previously thought to halt pigment 
production by the bacterium. However, the most remarkable finding was to observe the 
increased number of compounds in the pigment. Detailed HPLC analyses of the pigment have 
revealed that the pigments 1 and 2 actually consists of two compounds each, which was 
previously considered to be single compounds. This can give a reasonable explanation for the 
previous unsuccessful trial of determination of the chemical structure of the pigment 1 by 
NMR spectroscopy, which failed due to impurity of the sample. 
Our investigations have also revealed that the newly discovered P-1 is extremely 
unstable compared to other red pigment compounds, decomposing into other unknown yet 
compounds, thus making impossible to analyse its chemical structure. This was occurred 
despite keeping the pigments at cool temperature and without illumination, which is 
considered to be the stimulus for the degradation of the prodigiosin compounds. 
Decomposition of P-1 insisted on the precautions for the occurance of the same process with 
other pigments. Later, these suspicions were confirmed by HPLC analyses, where gradual 
decrease in the amounts of the pigments was observed. 
In order to investigate the factors that may cause the degradation of compounds, the 
impacts of the temperature and solvents were studied. The obtained results showed that both 
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of these factors might be essential in degradation of the red pigment compounds. Particularly, 
the pigment samples dissolved in DMSO and methanol and kept at room temperature 
conditions were tended to heavy degradations. However, this was the case with pigment 
samples that was not purified through silica gel. The pigment samples purified through silica 
gel have become more stable and kept for longer time without notable changes, though slowly 
decrease in the pigment concentrations were still observed. This suggests that the crude red 
pigment sample may contain polar small molecule compounds, which may initiate the 
degradation process of the pigments. These compounds might have mostly retained by silica 
gel during separation. The suspected compounds could not be detected on HPLC analyses as 
they might have not contained chromophore groups. 
Newly appeared compounds due to the decomposition of the pigments suggest that some 
of them might be derivatives of prodigiosin or contain the similar chromophore groups as they 
also appear near to the wavelength where prodigiosins give max absorbance. However, some 
additional peaks were also observed near to 300.0 nm in the UV spectrum, suggesting the 
difference of the nature of compounds. The decomposition process was also evident from the 
outer view of the samples whose color changed from red to brownish yellow colour. Drying 
of the red pigment samples by applying 39°C or above accelerated the irreversible 
decomposition, suggesting temperatures higher than the ambient to be crucial for the 
pigments stability. 
The chemical structure of P-2 was analysed using high resolution ESI-FTMS and 
different methods of NMR spectroscopy, including 1H-NMR, 13C-NMR, DEPT, HMQC, 
HMBC, NOESY, COSY and TOCSY. As a result of these investigations, the chemical 
structure of P-2 was elucidated to be 2-methyl-3-butylprodiginine, as previously proposed 
from the analysis of LC-MS/MS. 
Signal transduction pathways in eukaryotic cells are mostly regulated by precise control 
of phosphorylation and dephosphorylation levels of proteins, which can be controlled and 
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balanced by two classes of enzymes that work conversely to each other in the action, i.e. 
protein kinases and protein phosphatases [211]. It is an essential biochemical process, with 
estimated of 30% of all the cellular proteins to be phosphorylated [213]. The properly 
balanced phosphorylation-dephosphorylation process may provide a normal control of 
cellular responses to external stimuli. The abnormal activity of individual kinases and 
phosphatases associated with partly or fully inhibition and/or excessive induction may cause 
the pathogenesis in the cell, which leads to a variety of diseases, including cancer. Therefore, 
developing agents that can specifically inhibit the excessive activity of these enzymes have 
become an important issue as they represent potential drug candidates. Recently, protein 
kinases and protein phosphatases actively participating in the control of cell growth and 
differentiation by regulating the signal transduction pathway have become an attractive 
research tool to evaluate cellular viability in cytotoxicity studies. 
In this study, the effect of prodigiosin and violacein compounds were investigated on 
protein kinase and protein phosphatase enzymes activities as the possible targets in the 
apoptosis process of tumor cells. Selected members of kinase and phosphatase family 
enzymes were tested in vitro to assess the inhibitory effect of prodigiosins. Structure-activity 
relationship (SAR) studies of individual compounds of the red pigment were also investigated. 
The obtained results indicate that the chemical structures of the prodigiosin analogs are 
essential to cause apoptosis of cells and inhibition of protein phosphatases. Among the red 
pigment individual compounds, P-4 corresponding to prodigiosin, showed the highest 
apoptotic effect to all the tested leukemia cell lines, while the P-2 had the highest inhibitory 
effect on protein phosphatases, decreasing in the order of P-2 to P-7. 
Overall, the following conclusions were made according to the obtained and observed 
results: 
Regarding the prodigiosins stability and the structural analyses of P-2 
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1. Prodigiosin extract from strain 1020R was found to contain at least 7 prodigiosin 
compounds. 
2. P-1 copurified together with P-2 was found to be unstable, decomposing onto other 
unknown compound(s). 
3. For the first time in this study, P-2 was separated, purified and its chemical structure was 
elucidated to be 2-methyl-3-butylprodiginine [209]. 
4. Prodigiosin compounds were found to be sensitive to the temperature higher than 39°C. 
5. Silica gel separation was found to increase the stability of prodigiosins;. 
6. DMSO was found to be the most aggressive solvent to destroy the prodigiosins, followed 
by methanol, ethyl acetate, acetone, and 2-propanol. 
Regarding cytotoxicity of prodigiosins on leukemia cells 
7. Prodigiosin compounds showed apoptotic effect against U937, HL60, and K562 leukemia 
cells. 
8. P-4 (prodigiosin) was the strongest to induce apoptosis in U937, HL60, and K562 leukemia 
cells, while P-2 (2-methyl-3-butylprodiginine) showed the highest inhibitory effect against 
PP2A and PTP1B activities. 
Regarding inhibition of protein phosphatases by prodigiosins 
9. Until now, the effect of natural prodigiosin compounds on protein phosphatases was not 
reported, therefore, this is the first report to study their effect on protein phosphatases (PTP1B, 
PP2A). 
10. Prodigiosins from marine 1020R strain strongly inhibited the activity of protein 
phosphatases (PTP1B, PP2A), but had no or very low effects on protein kinases (PKA, PKC, 
PTK and CaM kinase) tested in this study. 
Regarding the effect of violacein on protein kinases and protein phosphatases 
11. Violacein effect on protein kinases A (PKA) and C (PKC) catalytic subunits was initially 
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investigated by Hosokawa and Enomoto, but its effect on PKC isozymes and other protein 
kinases as well as on protein phosphatases was studied in this study for the first time. 
12. Violacein showed inhibitory effects against classical PKC and some novel PKC, but was 
relatively inactive against other protein kinases (atypical PKC, PTK and CaM kinase). 
13. Violacein showed selective inhibitory effect against protein phosphatases tested in this 
study, inhibiting PP2A, but not PTP1B enzyme. 
Overall, these results suggest that the intracellular signal transduction pathway molecules 
might be involved in the cytotoxicity of prodigiosins and violacein towards malignant 
cancerous cells. This study also provides insight into the molecular mechanisms of 
cytotoxicity of prodigiosin compounds, the inhibitory effect of which against protein 
phosphatases gives a hope to be a potential drug candidate against type II diabetes and cancer. 
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Future perspectives 
The following suggestions seem to be interesting to investigate in the future: 
 To elucidate the chemical structures of P-1, P-3, and P-7, which are currently 
remaining unknown; 
 The exact factors that destabilise the prodigiosin compounds; 
 To investigate the inhibitory and/or activatory effect of the prodigiosin compounds to 
protein phosphatases (PP2A, PTP1B)-mediated signaling pathway. 
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